SEC Info - Shire plc - ‘10-Q’ for 3/31/10

SEC Info℠

Home

Help

Please Sign In

Shire plc – ‘10-Q’ for 3/31/10 – ‘EX-101.INS’

On: Thursday, 5/6/10, at 12:51pm ET · For: 3/31/10 · Accession #: 950103-10-1332 · File #: 0-29630

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/06/10  Shire plc                         10-Q        3/31/10   43:4.2M                                   Davis Polk & … LLP 01/FA

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    727K 
 2: EX-10.27    Material Contract                                   HTML    439K 
 3: EX-31.1     Certification -- §302 - SOA'02                      HTML     23K 
 4: EX-31.2     Certification -- §302 - SOA'02                      HTML     23K 
 5: EX-32.1     Certification -- §906 - SOA'02                      HTML     17K 
32: XML         IDEA XML File -- Definitions and References          XML     95K 
38: XML         IDEA XML File -- Filing Summary                      XML     65K 
36: XML.R1      Document And Entity Information                      XML    118K 
37: XML.R2      Unaudited Consolidated Balance Sheets                XML    332K 
19: XML.R3      Unaudited Consolidated Balance Sheets                XML     65K 
                (Parentheticals)                                                 
24: XML.R4      Unaudited Consolidated Balance Sheets                XML     33K 
                (Parentheticals in GBP)                                          
30: XML.R5      Unaudited Consolidated Statements of Income          XML    372K 
29: XML.R6      Unaudited Consolidated Statements of Income          XML     44K 
                (Parentheticals)                                                 
42: XML.R7      Unaudited Consolidated Statement of Changes in       XML    265K 
                Shareholders' Equity                                             
15: XML.R8      Unaudited Consolidated Statements of Comprehensive   XML     97K 
                Income                                                           
28: XML.R9      Unaudited Components of Accumulated Other            XML     58K 
                Comprehensive Income                                             
14: XML.R10     Unaudited Consolidated Statements of Comprehensive   XML     43K 
                Income (Parentheticals)                                          
13: XML.R11     Unaudited Consolidated Statements of Cash Flows      XML    402K 
18: XML.R12     Summary Of Significant Accounting Policies           XML     51K 
34: XML.R13     Business combinations                                XML     38K 
20: XML.R14     Termination costs                                    XML     40K 
21: XML.R15     Reorganization costs                                 XML     60K 
26: XML.R16     Accounts receivable, net                             XML     45K 
43: XML.R17     Inventories                                          XML     43K 
17: XML.R18     Prepaid expenses and other current assets            XML     41K 
12: XML.R19     Investments                                          XML     37K 
23: XML.R20     Other intangible assets, net                         XML     56K 
33: XML.R21     Accounts payable and accrued expenses                XML     45K 
16: XML.R22     Other current liabilities                            XML     40K 
31: XML.R23     Other non-current liabilities                        XML     41K 
22: XML.R24     Commitments and contingencies                        XML     80K 
41: XML.R25     Derivative instruments                               XML     63K 
35: XML.R26     Fair value measurement                               XML     72K 
25: XML.R27     Earnings per share                                   XML     54K 
27: XML.R28     Segmental reporting                                  XML     94K 
39: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS    103K 
 6: EX-101.INS  XBRL Instance -- shpgf-20100331                      XML    512K 
 8: EX-101.CAL  XBRL Calculations -- shpgf-20100331_cal              XML    199K 
 9: EX-101.DEF  XBRL Definitions -- shpgf-20100331_def               XML     82K 
10: EX-101.LAB  XBRL Labels -- shpgf-20100331_lab                    XML    822K 
11: EX-101.PRE  XBRL Presentations -- shpgf-20100331_pre             XML    466K 
 7: EX-101.SCH  XBRL Schema -- shpgf-20100331                        XSD     95K 
40: ZIP         XBRL Zipped Folder -- 0000950103-10-001332-xbrl      Zip     79K

‘EX-101.INS’ — XBRL Instance — shpgf-20100331

This Exhibit is an XBRL XML File.

<?xml version="1.0" encoding="windows-1252"?>

<xbrli:xbrl xmlns:shpgf="http://www.shire.com/20100331" xmlns:negated="http://xbrl.us/us-gaap/negated/2008-03-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.us/dei/2009-01-31" xmlns:us-roles="http://xbrl.us/us-roles/2009-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-types="http://xbrl.us/us-types/2009-01-31" xmlns:us-gaap="http://xbrl.us/us-gaap/2009-01-31" xmlns:ref="http://www.xbrl.org/2006/ref">

<link:schemaRef xlink:type="simple" xlink:href="shpgf-20100331.xsd"/>

<xbrli:context id="FROM_Jan01_2010_TO_Mar31_2010">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

</xbrli:entity>

<xbrli:period>

<xbrli:startDate> 2010-01-01 </xbrli:startDate>

<xbrli:endDate> 2010-03-31 </xbrli:endDate>

</xbrli:period>

</xbrli:context>

<xbrli:context id="FROM_Jan01_2009_TO_Mar31_2009">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

</xbrli:entity>

<xbrli:period>

<xbrli:startDate> 2009-01-01 </xbrli:startDate>

<xbrli:endDate> 2009-03-31 </xbrli:endDate>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Mar31_2010">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2010-03-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Dec31_2009">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2009-12-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Mar31_2010_shpgf_CommonShareParValueAxis_Commonstockparvaluemember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="shpgf:CommonShareParValueAxis"> shpgf:CommonStockParValueMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2010-03-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Dec31_2009_shpgf_CommonShareParValueAxis_Commonstockparvaluemember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="shpgf:CommonShareParValueAxis"> shpgf:CommonStockParValueMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2009-12-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Dec31_2009_us-gaap_StatementEquityComponentsAxis_Commonstockmember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2009-12-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Dec31_2009_us-gaap_StatementEquityComponentsAxis_Additionalpaidincapitalmember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2009-12-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Dec31_2009_us-gaap_StatementEquityComponentsAxis_Treasurystockmember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:TreasuryStockMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2009-12-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Dec31_2009_us-gaap_StatementEquityComponentsAxis_Accumulatedothercomprehensiveincomemember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2009-12-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Dec31_2009_us-gaap_StatementEquityComponentsAxis_Retainedearningsmember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2009-12-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:context id="FROM_Jan01_2010_TO_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Retainedearningsmember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:startDate> 2010-01-01 </xbrli:startDate>

<xbrli:endDate> 2010-03-31 </xbrli:endDate>

</xbrli:period>

</xbrli:context>

<xbrli:context id="FROM_Jan01_2010_TO_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Accumulatedothercomprehensiveincomemember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:startDate> 2010-01-01 </xbrli:startDate>

<xbrli:endDate> 2010-03-31 </xbrli:endDate>

</xbrli:period>

</xbrli:context>

<xbrli:context id="FROM_Jan01_2010_TO_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Commonclassamember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonClassAMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:startDate> 2010-01-01 </xbrli:startDate>

<xbrli:endDate> 2010-03-31 </xbrli:endDate>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Dec31_2009_us-gaap_StatementEquityComponentsAxis_Commonclassamember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonClassAMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2009-12-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:context id="FROM_Jan01_2010_TO_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Additionalpaidincapitalmember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:startDate> 2010-01-01 </xbrli:startDate>

<xbrli:endDate> 2010-03-31 </xbrli:endDate>

</xbrli:period>

</xbrli:context>

<xbrli:context id="FROM_Jan01_2010_TO_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Treasurystockmember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:TreasuryStockMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:startDate> 2010-01-01 </xbrli:startDate>

<xbrli:endDate> 2010-03-31 </xbrli:endDate>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Commonstockmember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2010-03-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Commonclassamember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonClassAMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2010-03-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Additionalpaidincapitalmember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2010-03-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Treasurystockmember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:TreasuryStockMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2010-03-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Accumulatedothercomprehensiveincomemember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2010-03-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Retainedearningsmember">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

<xbrli:segment>

<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>

</xbrli:segment>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2010-03-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Mar31_2009">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2009-03-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:context id="AS_OF_Dec31_2008">

<xbrli:entity>

<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0000936402 </xbrli:identifier>

</xbrli:entity>

<xbrli:period>

<xbrli:instant> 2008-12-31 </xbrli:instant>

</xbrli:period>

</xbrli:context>

<xbrli:unit id="USD">

<xbrli:measure> iso4217:USD </xbrli:measure>

</xbrli:unit>

<xbrli:unit id="shares">

<xbrli:measure> xbrli:shares </xbrli:measure>

</xbrli:unit>

<xbrli:unit id="GBP">

<xbrli:measure> iso4217:GBP </xbrli:measure>

</xbrli:unit>

<xbrli:unit id="EPS">

<xbrli:divide>

<xbrli:unitNumerator>

<xbrli:measure> iso4217:USD </xbrli:measure>

</xbrli:unitNumerator>

<xbrli:unitDenominator>

<xbrli:measure> xbrli:shares </xbrli:measure>

</xbrli:unitDenominator>

</xbrli:divide>

</xbrli:unit>

<dei:DocumentType id="ID_6294" contextRef="FROM_Jan01_2010_TO_Mar31_2010"> 10-Q </dei:DocumentType>

<dei:DocumentPeriodEndDate id="ID_6295" contextRef="FROM_Jan01_2010_TO_Mar31_2010"> 2010-03-31 </dei:DocumentPeriodEndDate>

<dei:AmendmentFlag id="ID_6296" contextRef="FROM_Jan01_2010_TO_Mar31_2010"> false </dei:AmendmentFlag>

<dei:EntityRegistrantName id="ID_6297" contextRef="FROM_Jan01_2010_TO_Mar31_2010"> Shire plc </dei:EntityRegistrantName>

<dei:EntityCentralIndexKey id="ID_6298" contextRef="FROM_Jan01_2010_TO_Mar31_2010"> 0000936402 </dei:EntityCentralIndexKey>

<dei:EntityCurrentReportingStatus id="ID_6299" contextRef="FROM_Jan01_2010_TO_Mar31_2010"> Yes </dei:EntityCurrentReportingStatus>

<dei:EntityVoluntaryFilers id="ID_6300" contextRef="FROM_Jan01_2010_TO_Mar31_2010"> No </dei:EntityVoluntaryFilers>

<dei:CurrentFiscalYearEndDate id="ID_6301" contextRef="FROM_Jan01_2010_TO_Mar31_2010"> --12-31 </dei:CurrentFiscalYearEndDate>

<dei:EntityFilerCategory id="ID_6302" contextRef="FROM_Jan01_2010_TO_Mar31_2010"> Large Accelerated Filer </dei:EntityFilerCategory>

<dei:EntityWellKnownSeasonedIssuer id="ID_6303" contextRef="FROM_Jan01_2010_TO_Mar31_2010"> Yes </dei:EntityWellKnownSeasonedIssuer>

<dei:EntityPublicFloat id="ID_6304" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 7709000000 </dei:EntityPublicFloat>

<dei:EntityCommonStockSharesOutstanding id="ID_6338" decimals="INF" contextRef="AS_OF_Mar31_2010" unitRef="shares"> 562110523 </dei:EntityCommonStockSharesOutstanding>

<dei:DocumentFiscalYearFocus id="ID_6530" contextRef="FROM_Jan01_2010_TO_Mar31_2010"> 2010 </dei:DocumentFiscalYearFocus>

<dei:DocumentFiscalPeriodFocus id="ID_6531" contextRef="FROM_Jan01_2010_TO_Mar31_2010"> Q1 </dei:DocumentFiscalPeriodFocus>

<us-gaap:CashAndCashEquivalentsAtCarryingValue id="ID_5792" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 498900000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>

<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue id="ID_5793" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 26800000 </us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>

<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue id="ID_5794" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 33100000 </us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>

<us-gaap:AccountsReceivableNetCurrent id="ID_5795" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 620700000 </us-gaap:AccountsReceivableNetCurrent>

<us-gaap:AccountsReceivableNetCurrent id="ID_5796" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 597500000 </us-gaap:AccountsReceivableNetCurrent>

<us-gaap:InventoryNet id="ID_5797" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 215600000 </us-gaap:InventoryNet>

<us-gaap:InventoryNet id="ID_5798" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 189700000 </us-gaap:InventoryNet>

<us-gaap:DeferredTaxAssetsNetCurrent id="ID_5801" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 114100000 </us-gaap:DeferredTaxAssetsNetCurrent>

<us-gaap:DeferredTaxAssetsNetCurrent id="ID_5802" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 135800000 </us-gaap:DeferredTaxAssetsNetCurrent>

<shpgf:PrepaidExpenseAndOtherAssetsCurrent id="ID_5803" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 131000000 </shpgf:PrepaidExpenseAndOtherAssetsCurrent>

<shpgf:PrepaidExpenseAndOtherAssetsCurrent id="ID_5804" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 115200000 </shpgf:PrepaidExpenseAndOtherAssetsCurrent>

<us-gaap:AssetsCurrent id="ID_5805" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 1765700000 </us-gaap:AssetsCurrent>

<us-gaap:AssetsCurrent id="ID_5806" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 1570200000 </us-gaap:AssetsCurrent>

<us-gaap:LongTermInvestments id="ID_5807" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 109600000 </us-gaap:LongTermInvestments>

<us-gaap:LongTermInvestments id="ID_5808" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 105700000 </us-gaap:LongTermInvestments>

<us-gaap:PropertyPlantAndEquipmentNet id="ID_5809" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 668500000 </us-gaap:PropertyPlantAndEquipmentNet>

<us-gaap:PropertyPlantAndEquipmentNet id="ID_5810" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 676800000 </us-gaap:PropertyPlantAndEquipmentNet>

<us-gaap:Goodwill id="ID_5811" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 373200000 </us-gaap:Goodwill>

<us-gaap:Goodwill id="ID_5812" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 384700000 </us-gaap:Goodwill>

<us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_5813" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 1729600000 </us-gaap:IntangibleAssetsNetExcludingGoodwill>

<us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_5814" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 1790700000 </us-gaap:IntangibleAssetsNetExcludingGoodwill>

<us-gaap:DeferredTaxAssetsNetNoncurrent id="ID_5815" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 80900000 </us-gaap:DeferredTaxAssetsNetNoncurrent>

<us-gaap:DeferredTaxAssetsNetNoncurrent id="ID_5816" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 79000000 </us-gaap:DeferredTaxAssetsNetNoncurrent>

<us-gaap:OtherAssetsNoncurrent id="ID_5817" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 11200000 </us-gaap:OtherAssetsNoncurrent>

<us-gaap:OtherAssetsNoncurrent id="ID_5818" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 10400000 </us-gaap:OtherAssetsNoncurrent>

<us-gaap:Assets id="ID_5819" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 4738700000 </us-gaap:Assets>

<us-gaap:Assets id="ID_5820" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 4617500000 </us-gaap:Assets>

<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="ID_5821" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 929200000 </us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>

<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="ID_5822" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 929100000 </us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>

<us-gaap:DeferredTaxLiabilitiesCurrent id="ID_5823" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 3300000 </us-gaap:DeferredTaxLiabilitiesCurrent>

<us-gaap:DeferredTaxLiabilitiesCurrent id="ID_5824" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 2900000 </us-gaap:DeferredTaxLiabilitiesCurrent>

<us-gaap:OtherLiabilitiesCurrent id="ID_5825" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 36500000 </us-gaap:OtherLiabilitiesCurrent>

<us-gaap:OtherLiabilitiesCurrent id="ID_5826" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 88000000 </us-gaap:OtherLiabilitiesCurrent>

<us-gaap:LiabilitiesCurrent id="ID_5827" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 969000000 </us-gaap:LiabilitiesCurrent>

<us-gaap:LiabilitiesCurrent id="ID_5828" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 1020000000 </us-gaap:LiabilitiesCurrent>

<us-gaap:ConvertibleDebtNoncurrent id="ID_5829" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 1100000000 </us-gaap:ConvertibleDebtNoncurrent>

<us-gaap:ConvertibleDebtNoncurrent id="ID_5830" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 1100000000 </us-gaap:ConvertibleDebtNoncurrent>

<us-gaap:LongTermDebtNoncurrent id="ID_5831" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 43700000 </us-gaap:LongTermDebtNoncurrent>

<us-gaap:LongTermDebtNoncurrent id="ID_5832" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 43600000 </us-gaap:LongTermDebtNoncurrent>

<us-gaap:DeferredTaxLiabilitiesNoncurrent id="ID_5833" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 321300000 </us-gaap:DeferredTaxLiabilitiesNoncurrent>

<us-gaap:DeferredTaxLiabilitiesNoncurrent id="ID_5834" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 294300000 </us-gaap:DeferredTaxLiabilitiesNoncurrent>

<us-gaap:OtherLiabilitiesNoncurrent id="ID_5835" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 247700000 </us-gaap:OtherLiabilitiesNoncurrent>

<us-gaap:OtherLiabilitiesNoncurrent id="ID_5836" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 247100000 </us-gaap:OtherLiabilitiesNoncurrent>

<us-gaap:Liabilities id="ID_5837" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 2681700000 </us-gaap:Liabilities>

<us-gaap:Liabilities id="ID_5838" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 2705000000 </us-gaap:Liabilities>

<us-gaap:CashAndCashEquivalentsAtCarryingValue id="ID_6452" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 657500000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>

<us-gaap:CommonStockValue id="ID_5839" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 55600000 </us-gaap:CommonStockValue>

<us-gaap:CommonStockValue id="ID_5840" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 55600000 </us-gaap:CommonStockValue>

<us-gaap:AdditionalPaidInCapitalCommonStock id="ID_5841" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 2697900000 </us-gaap:AdditionalPaidInCapitalCommonStock>

<us-gaap:AdditionalPaidInCapitalCommonStock id="ID_5842" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 2677600000 </us-gaap:AdditionalPaidInCapitalCommonStock>

<us-gaap:CommonStockSharesHeldInEmployeeTrust id="ID_5843" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 311800000 </us-gaap:CommonStockSharesHeldInEmployeeTrust>

<us-gaap:CommonStockSharesHeldInEmployeeTrust id="ID_5844" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 347400000 </us-gaap:CommonStockSharesHeldInEmployeeTrust>

<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="ID_5845" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 107300000 </us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>

<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="ID_5846" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 149100000 </us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>

<us-gaap:StockholdersEquity id="ID_5847" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 2057000000 </us-gaap:StockholdersEquity>

<us-gaap:StockholdersEquity id="ID_5848" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 1912500000 </us-gaap:StockholdersEquity>

<us-gaap:LiabilitiesAndStockholdersEquity id="ID_5852" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 4738700000 </us-gaap:LiabilitiesAndStockholdersEquity>

<us-gaap:LiabilitiesAndStockholdersEquity id="ID_5853" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 4617500000 </us-gaap:LiabilitiesAndStockholdersEquity>

<us-gaap:CommonStockSharesAuthorized id="ID_5854" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="shares"> 1000000000 </us-gaap:CommonStockSharesAuthorized>

<us-gaap:CommonStockSharesAuthorized id="ID_5855" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="shares"> 1000000000 </us-gaap:CommonStockSharesAuthorized>

<us-gaap:CommonStockSharesIssued id="ID_5856" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="shares"> 562100000 </us-gaap:CommonStockSharesIssued>

<us-gaap:CommonStockSharesIssued id="ID_5857" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="shares"> 561500000 </us-gaap:CommonStockSharesIssued>

<us-gaap:CommonStockSharesOutstanding id="ID_5858" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="shares"> 562100000 </us-gaap:CommonStockSharesOutstanding>

<us-gaap:CommonStockSharesOutstanding id="ID_5859" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="shares"> 561500000 </us-gaap:CommonStockSharesOutstanding>

<us-gaap:CommonStockSharesHeldInEmployeeTrustShares id="ID_5860" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="shares"> 15700000 </us-gaap:CommonStockSharesHeldInEmployeeTrustShares>

<us-gaap:CommonStockSharesHeldInEmployeeTrustShares id="ID_5861" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="shares"> 17800000 </us-gaap:CommonStockSharesHeldInEmployeeTrustShares>

<us-gaap:RetainedEarningsAccumulatedDeficit id="ID_5863" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> -492000000 </us-gaap:RetainedEarningsAccumulatedDeficit>

<us-gaap:RetainedEarningsAccumulatedDeficit id="ID_5864" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> -622400000 </us-gaap:RetainedEarningsAccumulatedDeficit>

<us-gaap:CommonStockParOrStatedValuePerShare id="ID_5868" decimals="2" contextRef="AS_OF_Mar31_2010_shpgf_CommonShareParValueAxis_Commonstockparvaluemember" unitRef="GBP"> 0.05 </us-gaap:CommonStockParOrStatedValuePerShare>

<us-gaap:CommonStockParOrStatedValuePerShare id="ID_5869" decimals="2" contextRef="AS_OF_Dec31_2009_shpgf_CommonShareParValueAxis_Commonstockparvaluemember" unitRef="GBP"> 0.05 </us-gaap:CommonStockParOrStatedValuePerShare>

<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_6453" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 2057000000 </us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_6454" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 1912500000 </us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

<us-gaap:SalesRevenueGoodsNet id="ID_5872" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 718200000 </us-gaap:SalesRevenueGoodsNet>

<us-gaap:SalesRevenueGoodsNet id="ID_5873" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 756000000 </us-gaap:SalesRevenueGoodsNet>

<us-gaap:RoyaltyRevenue id="ID_5875" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 95300000 </us-gaap:RoyaltyRevenue>

<us-gaap:RoyaltyRevenue id="ID_5876" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 50600000 </us-gaap:RoyaltyRevenue>

<us-gaap:OtherSalesRevenueNet id="ID_5878" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 2700000 </us-gaap:OtherSalesRevenueNet>

<us-gaap:OtherSalesRevenueNet id="ID_5879" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 11200000 </us-gaap:OtherSalesRevenueNet>

<us-gaap:Revenues id="ID_5881" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 816200000 </us-gaap:Revenues>

<us-gaap:Revenues id="ID_5882" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 817800000 </us-gaap:Revenues>

<us-gaap:CostOfGoodsSold id="ID_5884" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 101900000 </us-gaap:CostOfGoodsSold>

<us-gaap:CostOfGoodsSold id="ID_5885" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 83600000 </us-gaap:CostOfGoodsSold>

<us-gaap:ResearchAndDevelopmentExpense id="ID_5887" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 131000000 </us-gaap:ResearchAndDevelopmentExpense>

<us-gaap:ResearchAndDevelopmentExpense id="ID_5888" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 185900000 </us-gaap:ResearchAndDevelopmentExpense>

<us-gaap:SellingGeneralAndAdministrativeExpense id="ID_5890" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 359900000 </us-gaap:SellingGeneralAndAdministrativeExpense>

<us-gaap:SellingGeneralAndAdministrativeExpense id="ID_5891" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 318900000 </us-gaap:SellingGeneralAndAdministrativeExpense>

<us-gaap:ReorganizationItems id="ID_5899" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 5000000 </us-gaap:ReorganizationItems>

<us-gaap:ReorganizationItems id="ID_5900" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 2200000 </us-gaap:ReorganizationItems>

<us-gaap:BusinessCombinationAcquisitionRelatedCosts id="ID_5902" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 600000 </us-gaap:BusinessCombinationAcquisitionRelatedCosts>

<us-gaap:BusinessCombinationAcquisitionRelatedCosts id="ID_5903" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 1400000 </us-gaap:BusinessCombinationAcquisitionRelatedCosts>

<us-gaap:OperatingExpenses id="ID_5905" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 598400000 </us-gaap:OperatingExpenses>

<us-gaap:OperatingExpenses id="ID_5906" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 592000000 </us-gaap:OperatingExpenses>

<us-gaap:OperatingIncomeLoss id="ID_5908" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 217800000 </us-gaap:OperatingIncomeLoss>

<us-gaap:OperatingIncomeLoss id="ID_5909" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 225800000 </us-gaap:OperatingIncomeLoss>

<us-gaap:InterestIncomeDepositsWithFinancialInstitutions id="ID_5911" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 400000 </us-gaap:InterestIncomeDepositsWithFinancialInstitutions>

<us-gaap:InterestIncomeDepositsWithFinancialInstitutions id="ID_5912" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 600000 </us-gaap:InterestIncomeDepositsWithFinancialInstitutions>

<shpgf:InterestExpenseNonOperating id="ID_5914" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 9000000 </shpgf:InterestExpenseNonOperating>

<shpgf:InterestExpenseNonOperating id="ID_5915" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 11000000 </shpgf:InterestExpenseNonOperating>

<us-gaap:OtherNonoperatingIncomeExpense id="ID_5917" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 10800000 </us-gaap:OtherNonoperatingIncomeExpense>

<us-gaap:OtherNonoperatingIncomeExpense id="ID_5918" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 50300000 </us-gaap:OtherNonoperatingIncomeExpense>

<us-gaap:NonoperatingIncomeExpense id="ID_5920" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 2200000 </us-gaap:NonoperatingIncomeExpense>

<us-gaap:NonoperatingIncomeExpense id="ID_5921" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 39900000 </us-gaap:NonoperatingIncomeExpense>

<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="ID_5923" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 220000000 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>

<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="ID_5924" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 265700000 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>

<us-gaap:IncomeTaxExpenseBenefit id="ID_5926" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 53600000 </us-gaap:IncomeTaxExpenseBenefit>

<us-gaap:IncomeTaxExpenseBenefit id="ID_5927" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 49500000 </us-gaap:IncomeTaxExpenseBenefit>

<us-gaap:IncomeLossFromEquityMethodInvestments id="ID_5929" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> -500000 </us-gaap:IncomeLossFromEquityMethodInvestments>

<us-gaap:IncomeLossFromEquityMethodInvestments id="ID_5930" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> -100000 </us-gaap:IncomeLossFromEquityMethodInvestments>

<us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest id="ID_5932" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 165900000 </us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>

<us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest id="ID_5933" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 216100000 </us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>

<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="ID_5936" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> -2600000 </us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>

<us-gaap:ProfitLoss id="ID_5938" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 165900000 </us-gaap:ProfitLoss>

<us-gaap:ProfitLoss id="ID_5939" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 213500000 </us-gaap:ProfitLoss>

<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="ID_5942" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> -100000 </us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>

<us-gaap:NetIncomeLoss id="ID_5944" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 165900000 </us-gaap:NetIncomeLoss>

<us-gaap:NetIncomeLoss id="ID_5945" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 213600000 </us-gaap:NetIncomeLoss>

<us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation id="ID_5947" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 0 </us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>

<us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation id="ID_5948" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 0 </us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>

<us-gaap:IncomeLossFromContinuingOperationsPerBasicShare id="ID_5950" decimals="INF" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="EPS"> 0.305 </us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>

<us-gaap:IncomeLossFromContinuingOperationsPerBasicShare id="ID_5951" decimals="INF" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="EPS"> 0.401 </us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>

<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare id="ID_5954" decimals="INF" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="EPS"> -0.005 </us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>

<us-gaap:EarningsPerShareBasic id="ID_5956" decimals="INF" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="EPS"> 0.305 </us-gaap:EarningsPerShareBasic>

<us-gaap:EarningsPerShareBasic id="ID_5957" decimals="INF" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="EPS"> 0.396 </us-gaap:EarningsPerShareBasic>

<us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare id="ID_5959" decimals="INF" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="EPS"> 0.297 </us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>

<us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare id="ID_5960" decimals="INF" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="EPS"> 0.389 </us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>

<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare id="ID_5963" decimals="INF" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="EPS"> -0.004 </us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>

<us-gaap:EarningsPerShareDiluted id="ID_5965" decimals="INF" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="EPS"> 0.297 </us-gaap:EarningsPerShareDiluted>

<us-gaap:EarningsPerShareDiluted id="ID_5966" decimals="INF" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="EPS"> 0.385 </us-gaap:EarningsPerShareDiluted>

<us-gaap:WeightedAverageNumberOfSharesIssuedBasic id="ID_5968" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="shares"> 543900000 </us-gaap:WeightedAverageNumberOfSharesIssuedBasic>

<us-gaap:WeightedAverageNumberOfSharesIssuedBasic id="ID_5969" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="shares"> 539200000 </us-gaap:WeightedAverageNumberOfSharesIssuedBasic>

<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="ID_5971" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="shares"> 586100000 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>

<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="ID_5972" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="shares"> 577200000 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>

<us-gaap:IncomeLossFromContinuingOperations id="ID_5762" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 165900000 </us-gaap:IncomeLossFromContinuingOperations>

<us-gaap:IncomeLossFromContinuingOperations id="ID_5763" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 216200000 </us-gaap:IncomeLossFromContinuingOperations>

<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity id="ID_5767" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> -2600000 </us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>

<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_6460" decimals="-5" contextRef="AS_OF_Dec31_2009_us-gaap_StatementEquityComponentsAxis_Commonstockmember" unitRef="USD"> 55600000 </us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_6461" decimals="-5" contextRef="AS_OF_Dec31_2009_us-gaap_StatementEquityComponentsAxis_Additionalpaidincapitalmember" unitRef="USD"> 2677600000 </us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_6462" decimals="-5" contextRef="AS_OF_Dec31_2009_us-gaap_StatementEquityComponentsAxis_Treasurystockmember" unitRef="USD"> -347400000 </us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_6463" decimals="-5" contextRef="AS_OF_Dec31_2009_us-gaap_StatementEquityComponentsAxis_Accumulatedothercomprehensiveincomemember" unitRef="USD"> 149100000 </us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_6464" decimals="-5" contextRef="AS_OF_Dec31_2009_us-gaap_StatementEquityComponentsAxis_Retainedearningsmember" unitRef="USD"> -622400000 </us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

<us-gaap:ProfitLoss id="ID_6465" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Retainedearningsmember" unitRef="USD"> 165900000 </us-gaap:ProfitLoss>

<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease id="ID_6466" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Accumulatedothercomprehensiveincomemember" unitRef="USD"> -35100000 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>

<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="ID_6467" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Commonclassamember" unitRef="shares"> 600000 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

<us-gaap:SharesIssued id="ID_6468" decimals="-5" contextRef="AS_OF_Dec31_2009_us-gaap_StatementEquityComponentsAxis_Commonclassamember" unitRef="shares"> 561500000 </us-gaap:SharesIssued>

<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="ID_6469" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Additionalpaidincapitalmember" unitRef="USD"> 1400000 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_6470" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Additionalpaidincapitalmember" unitRef="USD"> 14100000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

<shpgf:SharesReleasedDuringPeriodByESOT id="ID_6471" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Retainedearningsmember" unitRef="USD"> -35500000 </shpgf:SharesReleasedDuringPeriodByESOT>

<shpgf:SharesReleasedDuringPeriodByESOT id="ID_6472" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Treasurystockmember" unitRef="USD"> 35600000 </shpgf:SharesReleasedDuringPeriodByESOT>

<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="ID_6473" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Accumulatedothercomprehensiveincomemember" unitRef="USD"> -6700000 </us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>

<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_6474" decimals="-5" contextRef="AS_OF_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Commonstockmember" unitRef="USD"> 55600000 </us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

<us-gaap:SharesIssued id="ID_6475" decimals="-5" contextRef="AS_OF_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Commonclassamember" unitRef="shares"> 562100000 </us-gaap:SharesIssued>

<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_6476" decimals="-5" contextRef="AS_OF_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Additionalpaidincapitalmember" unitRef="USD"> 2697900000 </us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_6477" decimals="-5" contextRef="AS_OF_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Treasurystockmember" unitRef="USD"> -311800000 </us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_6478" decimals="-5" contextRef="AS_OF_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Accumulatedothercomprehensiveincomemember" unitRef="USD"> 107300000 </us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_6479" decimals="-5" contextRef="AS_OF_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Retainedearningsmember" unitRef="USD"> -492000000 </us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

<us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions id="ID_6518" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010_us-gaap_StatementEquityComponentsAxis_Additionalpaidincapitalmember" unitRef="USD"> -4800000 </us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions>

<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="ID_6537" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 1400000 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_6538" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 14100000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

<us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions id="ID_6539" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> -4800000 </us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityEmployeeStockOptions>

<shpgf:SharesReleasedDuringPeriodByESOT id="ID_6540" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 100000 </shpgf:SharesReleasedDuringPeriodByESOT>

<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease id="ID_5770" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> -35100000 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>

<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="ID_5773" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> -6700000 </us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>

<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest id="ID_5778" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 124100000 </us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>

<us-gaap:ComprehensiveIncomeNetOfTax id="ID_6100" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 124100000 </us-gaap:ComprehensiveIncomeNetOfTax>

<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease id="ID_6206" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 13800000 </us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>

<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="ID_6207" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 600000 </us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>

<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest id="ID_6210" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 227900000 </us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>

<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest id="ID_6211" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> -100000 </us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>

<us-gaap:ComprehensiveIncomeNetOfTax id="ID_6213" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 228000000 </us-gaap:ComprehensiveIncomeNetOfTax>

<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax id="ID_6431" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 1600000 </us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>

<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax id="ID_6561" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 0 </us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>

<us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax id="ID_5784" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 101600000 </us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>

<us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax id="ID_5785" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 136700000 </us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>

<us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="ID_5786" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 5700000 </us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>

<us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax id="ID_5787" decimals="-5" contextRef="AS_OF_Dec31_2009" unitRef="USD"> 12400000 </us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>

<us-gaap:DepreciationAndAmortization id="ID_6116" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 64300000 </us-gaap:DepreciationAndAmortization>

<us-gaap:DepreciationAndAmortization id="ID_6117" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 55300000 </us-gaap:DepreciationAndAmortization>

<us-gaap:ShareBasedCompensation id="ID_6119" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 14100000 </us-gaap:ShareBasedCompensation>

<us-gaap:ShareBasedCompensation id="ID_6120" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 15800000 </us-gaap:ShareBasedCompensation>

<us-gaap:GainLossOnSaleOfInvestments id="ID_6130" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 11100000 </us-gaap:GainLossOnSaleOfInvestments>

<us-gaap:GainLossOnSaleOfInvestments id="ID_6131" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 55200000 </us-gaap:GainLossOnSaleOfInvestments>

<us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesOther id="ID_6136" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 5200000 </us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesOther>

<us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesOther id="ID_6137" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 3300000 </us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesOther>

<us-gaap:IncreaseDecreaseInDeferredIncomeTaxes id="ID_6139" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> -52200000 </us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>

<us-gaap:IncreaseDecreaseInDeferredIncomeTaxes id="ID_6140" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> -33700000 </us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>

<us-gaap:IncreaseDecreaseInAccountsReceivable id="ID_6145" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 10800000 </us-gaap:IncreaseDecreaseInAccountsReceivable>

<us-gaap:IncreaseDecreaseInAccountsReceivable id="ID_6146" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 151000000 </us-gaap:IncreaseDecreaseInAccountsReceivable>

<shpgf:IncreaseDecreaseInSalesDeductionAccrual id="ID_6148" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 64900000 </shpgf:IncreaseDecreaseInSalesDeductionAccrual>

<shpgf:IncreaseDecreaseInSalesDeductionAccrual id="ID_6149" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 121900000 </shpgf:IncreaseDecreaseInSalesDeductionAccrual>

<us-gaap:IncreaseDecreaseInInventories id="ID_6151" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 24200000 </us-gaap:IncreaseDecreaseInInventories>

<us-gaap:IncreaseDecreaseInInventories id="ID_6152" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 9500000 </us-gaap:IncreaseDecreaseInInventories>

<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="ID_6154" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 18100000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>

<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="ID_6155" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 12300000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>

<us-gaap:IncreaseDecreaseInOtherOperatingAssets id="ID_6157" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 600000 </us-gaap:IncreaseDecreaseInOtherOperatingAssets>

<us-gaap:IncreaseDecreaseInOtherOperatingAssets id="ID_6158" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> -3400000 </us-gaap:IncreaseDecreaseInOtherOperatingAssets>

<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="ID_6160" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> -116100000 </us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="ID_6161" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> -39800000 </us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

<us-gaap:EquityMethodInvestmentDividendsOrDistributions id="ID_6164" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 4900000 </us-gaap:EquityMethodInvestmentDividendsOrDistributions>

<us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations id="ID_6168" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> -2600000 </us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>

<us-gaap:NetCashProvidedByUsedInOperatingActivities id="ID_6169" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 186200000 </us-gaap:NetCashProvidedByUsedInOperatingActivities>

<us-gaap:NetCashProvidedByUsedInOperatingActivities id="ID_6170" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 184100000 </us-gaap:NetCashProvidedByUsedInOperatingActivities>

<us-gaap:IncreaseDecreaseInRestrictedCash id="ID_6173" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> -6300000 </us-gaap:IncreaseDecreaseInRestrictedCash>

<us-gaap:IncreaseDecreaseInRestrictedCash id="ID_6174" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 6900000 </us-gaap:IncreaseDecreaseInRestrictedCash>

<us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates id="ID_6177" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 74100000 </us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>

<us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment id="ID_6182" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 43600000 </us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>

<us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment id="ID_6183" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 42000000 </us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>

<us-gaap:PaymentsToAcquireIntangibleAssets id="ID_6186" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 6000000 </us-gaap:PaymentsToAcquireIntangibleAssets>

<us-gaap:ProceedsFromSaleOfOtherInvestments id="ID_6188" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 2000000 </us-gaap:ProceedsFromSaleOfOtherInvestments>

<us-gaap:ProceedsFromSaleOfOtherInvestments id="ID_6189" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 19200000 </us-gaap:ProceedsFromSaleOfOtherInvestments>

<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="ID_6191" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 100000 </us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>

<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="ID_6192" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 400000 </us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>

<shpgf:EquityMethodInvestmentReturns id="ID_6198" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> -200000 </shpgf:EquityMethodInvestmentReturns>

<us-gaap:NetCashProvidedByUsedInInvestingActivities id="ID_6200" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> -35200000 </us-gaap:NetCashProvidedByUsedInInvestingActivities>

<us-gaap:NetCashProvidedByUsedInInvestingActivities id="ID_6201" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> -109200000 </us-gaap:NetCashProvidedByUsedInInvestingActivities>

<us-gaap:RepaymentsOfLongTermDebt id="ID_5985" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 700000 </us-gaap:RepaymentsOfLongTermDebt>

<us-gaap:RepaymentsOfLongTermDebt id="ID_5986" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 700000 </us-gaap:RepaymentsOfLongTermDebt>

<us-gaap:ProceedsFromStockOptionsExercised id="ID_5987" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 1500000 </us-gaap:ProceedsFromStockOptionsExercised>

<us-gaap:ProceedsFromStockOptionsExercised id="ID_5988" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 100000 </us-gaap:ProceedsFromStockOptionsExercised>

<us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities id="ID_5997" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 4800000 </us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>

<us-gaap:NetCashProvidedByUsedInFinancingActivities id="ID_6326" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 5600000 </us-gaap:NetCashProvidedByUsedInFinancingActivities>

<us-gaap:NetCashProvidedByUsedInFinancingActivities id="ID_6327" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> -600000 </us-gaap:NetCashProvidedByUsedInFinancingActivities>

<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="ID_6329" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 2000000 </us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>

<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="ID_6330" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> -1400000 </us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>

<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="ID_6335" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> 158600000 </us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="ID_6336" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 72900000 </us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

<us-gaap:CashAndCashEquivalentsAtCarryingValue id="ID_6525" decimals="-5" contextRef="AS_OF_Dec31_2008" unitRef="USD"> 218200000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>

<us-gaap:CashAndCashEquivalentsAtCarryingValue id="ID_6526" decimals="-5" contextRef="AS_OF_Mar31_2009" unitRef="USD"> 291100000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>

<us-gaap:InterestPaid id="ID_6354" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> -700000 </us-gaap:InterestPaid>

<us-gaap:InterestPaid id="ID_6355" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> -1700000 </us-gaap:InterestPaid>

<us-gaap:IncomeTaxesPaid id="ID_6357" decimals="-5" contextRef="FROM_Jan01_2010_TO_Mar31_2010" unitRef="USD"> -89700000 </us-gaap:IncomeTaxesPaid>

<us-gaap:IncomeTaxesPaid id="ID_6358" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> -50400000 </us-gaap:IncomeTaxesPaid>

<us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived id="ID_6360" decimals="-5" contextRef="AS_OF_Mar31_2010" unitRef="USD"> 9100000 </us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived>

<us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived id="ID_6523" decimals="-5" contextRef="AS_OF_Mar31_2009" unitRef="USD"> 50800000 </us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived>

<shpgf:BuildingFinancingObligation id="ID_6524" decimals="-5" contextRef="FROM_Jan01_2009_TO_Mar31_2009" unitRef="USD"> 8500000 </shpgf:BuildingFinancingObligation>

<us-gaap:SignificantAccountingPoliciesTextBlock id="ID_6556" contextRef="FROM_Jan01_2010_TO_Mar31_2010">

1. Summary of Significant Accounting Policies (a) Basis of preparation These interim financial statements of Shire plc and its subsidiaries (collectively "Shire" or "the Company") and other financial information included in this Form 10-Q, are unaudited. They have been prepared in accordance with generally accepted accounting principles in the United States of America ("US GAAP") and US Securities and Exchange Commission ("SEC") regulations for interim reporting. The December 31, 2009 balance sheet was derived from audited financial statements but does not include all disclosures required by US GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading.These interim financial statements should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company's Annual Report on Form 10-K for the year to December 31, 2009.Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. Interim results are not necessarily indicative of results to be expected for the full year. (b) Use of estimates in interim financial statements The preparation of interim financial statements, in conformity with US GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions are primarily made in relation to the valuation of intangible assets, the valuation of equity investments, sales deductions, income taxes and provisions for litigation and legal proceedings. (c) New accounting pronouncements Adopted during the period Amendments to the Accounting and Disclosure Requirements for the Consolidation of Variable Interest Entities On January 1, 2010 the Company adopted new guidance issued by the Financial Accounting Standard Board ("FASB") on the consolidation of variable interest entities. This guidance changes how a reporting entity determines when an entity that is insufficiently capitalized or is not controlled through voting (or similar rights) should be consolidated. The determination of whether a reporting entity is required to consolidate another entity is based on, among other things, the other entity's purpose and design and the reporting entity's ability to direct the activities of the other entity that most significantly impact the other entity's economic performance. The guidance also requires a reporting entity to provide additional disclosures about its involvement with variable interest entities and any significant changes in risk exposure due to such involvement. The adoption of the guidance did not impact the Company's consolidated financial position, results of operations or cash flows. The effective date of these amendments has been deferred for a reporting entity's interest in an entity (1) that has all the attributes of an investment company or (2) for which it is industry practice to apply measurement principles for financial reporting purposes that are consistent with those followed by investment companies. Accounting for Transfers of Financial Assets On January 1, 2010 the Company adopted new guidance issued by the FASB on the accounting for transfers of financial assets. This guidance requires more information about transfers of financial assets, including securitization transactions, and where entities have continuing exposure to the risks related to transferred financial assets. It eliminates the concept of a "qualifying special-purpose entity," changes the requirements for derecognizing financial assets, and requires additional disclosures. The adoption of the guidance did not impact the Company's consolidated financial position, results of operations or cash flows. Improving Disclosures about Fair Value Measurements On January 1, 2010 the Company adopted new guidance issued by the FASB requiring new disclosures for amounts transferred in and out of Levels 1 and 2 and for activity in Level 3 of the hierarchy for fair value measurements. The guidance also clarifies existing fair value measurement disclosures in respect of the level of disaggregation and disclosures about inputs and valuation techniques. This guidance is effective for Shire from January 1, 2010, except for the additional disclosures about activity in Level 3 of the hierarchy for fair value measurements, which is effective from January 1, 2011 and for interim periods within that year. The adoption of the guidance did not impact the Company's disclosure on fair value measurement. To be adopted in future periods Revenue Recognition in Multiple Deliverable Revenue Arrangements In September 2009, the FASB issued guidance on revenue recognition in multiple deliverable revenue arrangements. This amends the existing guidance on allocating consideration received between the elements in a multiple-deliverable arrangement and establishes a selling price hierarchy for determining the selling price of a deliverable. The selling price used for each deliverable will be based on vendor specific objective evidence ("VSOE") if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE or third party evidence is available. It replaces the term fair value in the revenue allocation with selling price to clarify that the allocation of revenue is based on entity specific assumptions rather then the assumptions of a market place participant. The guidance will eliminate the residual method of allocation and requires that arrangement consideration be allocated using the relative selling price method. It will also significantly expand the disclosures related to a vendor's multiple-deliverable revenue arrangements. It will be effective prospectively for revenue arrangements entered into or materially modified for fiscal years beginning on or after June 15, 2010. The Company is currently evaluating the impact of adopting this guidance. Effect of Denominating the Exercise Price of a Share-Based Payment Award in the Currency of the Market in Which the Underlying Equity Security Trades In April 2010, the FASB issued guidance on the effect of denominating the exercise price of a share-based payment award in the currency of the market in which the underlying equity security trades. This guidance clarifies that an employee share-based payment award with an exercise price denominated in the currency of a market in which a substantial portion of the entity's equity securities trades should not be considered to contain a condition that is not a market, performance, or service condition. Therefore, an entity would not classify such an award as a liability if it otherwise qualifies as equity. The guidance will be effective for fiscal years beginning on or after December 15, 2010. The Company is currently evaluating the impact of adopting this guidance. Milestone Method of Revenue Recognition In April 2010, the FASB issued guidance on defining a milestone and determining when it may be appropriate to apply the milestone method of revenue recognition for research or development transactions. This guidance clarifies that: consideration that is contingent on achievement of a milestone in its entirety may be recognized as revenue in the period in which the milestone is achieved only if the milestone is judged to meet certain criteria to be considered substantive; milestones should be considered substantive in their entirety and may not be bifurcated; an arrangement may contain both substantive and nonsubstantive milestones; and each milestone should be evaluated individually to determine if it is substantive. The guidance will be effective on a prospective basis for milestones achieved in fiscal years, and interim periods within those years, beginning on or after June 15, 2010. Early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance.

</us-gaap:SignificantAccountingPoliciesTextBlock>

<us-gaap:BusinessCombinationDisclosureTextBlock id="ID_6481" contextRef="FROM_Jan01_2010_TO_Mar31_2010">

2. Business combinations On March 31, 2009 the Company acquired the worldwide rights (excluding the US, Canada and Barbados) to EQUASYM IR and XL for the treatment of attention deficit and hyperactivity disorder ("ADHD") from UCB Pharma Limited ("UCB") for cash consideration of $72.8 million. Included within the recognized purchase price for the acquisition is further consideration of $18.2 million, which may become payable in 2010 and 2011 if certain sales targets are met. This acquisition broadened the scope of Shire's ADHD portfolio and facilitated immediate access to the European ADHD market as well as providing Shire the opportunity to enter additional markets around the world. The acquisition of EQUASYM IR and XL was accounted for as a business combination. The purchase price was allocated to the currently marketed products acquired ($73.0 million), IPR&D ($5.5 million), other liabilities ($0.7 million) and goodwill ($13.2 million).

</us-gaap:BusinessCombinationDisclosureTextBlock>

<shpgf:TerminationCostsTextBlock id="ID_6482" contextRef="FROM_Jan01_2010_TO_Mar31_2010">

3. Termination of Duramed Pharmaceuticals, Inc. ("Duramed") collaboration agreement In August 2006, Shire and Duramed, a subsidiary of Teva Pharmaceutical Industries Ltd, ("Teva") entered into an agreement related to SEASONIQUE, a number of products using Duramed's transvaginal ring technology and other oral products (the "Collaboration Products"). On February 24, 2009 Shire and Duramed amended this agreement such that it terminated on December 31, 2009. Pursuant to this amendment, Shire returned to Duramed its rights under the agreement effective February 24, 2009 and charged contract termination costs totaling $65.0 million to research and development in the three months to March 31, 2009. All contract termination costs have been paid by March 31, 2010. <div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 34px"><td style="width: 320px; text-align:left;border-color:#000000;min-width:320px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">Opening liability at January 1, 2010</td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;">Amount paid </td><td style="width: 131px; text-align:right;border-color:#000000;min-width:131px;">Closing liability at March 31, 2010</td></tr><tr style="height: 17px"><td style="width: 320px; text-align:left;border-color:#000000;min-width:320px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">$’M</td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;">$’M</td><td style="width: 131px; text-align:right;border-color:#000000;min-width:131px;">$’M</td></tr><tr style="height: 11px"><td style="width: 320px; text-align:left;border-color:#000000;min-width:320px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">______________________</td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;">_____________________</td><td style="width: 131px; text-align:right;border-color:#000000;min-width:131px;">_______________</td></tr><tr style="height: 11px"><td style="width: 320px; text-align:left;border-color:#000000;min-width:320px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;"> </td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;"> </td><td style="width: 131px; text-align:right;border-color:#000000;min-width:131px;"> </td></tr><tr style="height: 17px"><td style="width: 320px; text-align:left;border-color:#000000;min-width:320px;">Contract termination costs</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">10.0</td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;">(10.0)</td><td style="width: 131px; text-align:right;border-color:#000000;min-width:131px;">- </td></tr><tr style="height: 11px"><td style="width: 320px; text-align:left;border-color:#000000;min-width:320px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">______________________</td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;">_____________________</td><td style="width: 131px; text-align:right;border-color:#000000;min-width:131px;">_______________</td></tr></table></div>

</shpgf:TerminationCostsTextBlock>

<shpgf:ReorganizationItemsTextBlock id="ID_6560" contextRef="FROM_Jan01_2010_TO_Mar31_2010">

4. Reorganization costs Establishment of Swiss Commercial Hub In the three months to March 31, 2010, the Company initiated plans to relocate certain commercial and R&D operations to Switzerland over the next two years, and incurred reorganization costs totaling $1.6 million during the period. Owings Mills In March 2009 the Company initiated plans to phase out operations and close the Company's Specialty Pharmaceuticals manufacturing facility at Owings Mills, Maryland. Between 2009 and 2011, all products manufactured by Shire at this site will transition to DSM Pharmaceutical Products, and operations and employee numbers at the site will wind down over this period. During the three months to March 31, 2010 the Company incurred reorganization costs of $3.4 million which relate to employee involuntary termination benefits and other costs. The total reorganization costs incurred since March 2009 are $16.1 million. As a result of the decision to transfer manufacturing from the Owings Mills site the Company revised the useful life of property, plant and equipment in the facility, and in the three months to March 31, 2010 incurred accelerated depreciation of $6.1 million, which has been charged to Cost of product sales. Consequently, the Company estimates an annual accelerated depreciation charge, over the level which would have been charged absent the wind down of operations, of $16.9 million in 2010. The reorganization costs and accelerated depreciation have been recorded within the Specialty Pharmaceuticals reportable segment. Jerini non-core operations In the second quarter of 2009 the operations of Jerini Ophthalmic, Inc, ("JOI") and certain other non-core pre-clinical operations acquired through the acquisition of Jerini AG ("Jerini") were closed down, and the Company recorded a closure costs liability of $9.1 million, relating to employee involuntary termination benefits and other closure costs. At March 31, 2010 a liability of $1.6 million remained for these closure costs. The liability for reorganization costs arising on the establishment of the Swiss commercial hub, transfer of manufacturing from Owings Mills and the Jerini closure at March 31, 2010 is as follows:<div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td style="width: 282px; text-align:left;border-color:#000000;min-width:282px;"> </td><td style="width: 114px; text-align:left;border-color:#000000;min-width:114px;"> </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;"> </td></tr><tr style="height: 17px"><td style="width: 282px; text-align:left;border-color:#000000;min-width:282px;"> </td><td style="width: 114px; text-align:right;border-color:#000000;min-width:114px;">Opening liability</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">Amount</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;">Closing</td></tr><tr style="height: 17px"><td style="width: 282px; text-align:left;border-color:#000000;min-width:282px;"> </td><td style="width: 114px; text-align:right;border-color:#000000;min-width:114px;">at January 1,</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">charged to re-</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;">liability at</td></tr><tr style="height: 17px"><td style="width: 282px; text-align:left;border-color:#000000;min-width:282px;"> </td><td style="width: 114px; text-align:right;border-color:#000000;min-width:114px;">2010</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">organization</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">Paid/Utilized</td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;">March 31, 2010</td></tr><tr style="height: 17px"><td style="width: 282px; text-align:left;border-color:#000000;min-width:282px;"> </td><td style="width: 114px; text-align:right;border-color:#000000;min-width:114px;">$'M</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">$'M</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">$'M</td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;">$'M</td></tr><tr style="height: 11px"><td style="width: 282px; text-align:right;border-color:#000000;min-width:282px;"> </td><td style="width: 114px; text-align:right;border-color:#000000;min-width:114px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;">___________</td></tr><tr style="height: 17px"><td style="width: 282px; text-align:left;border-color:#000000;min-width:282px;"> </td><td style="width: 114px; text-align:right;border-color:#000000;min-width:114px;"> </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;"> </td></tr><tr style="height: 19px"><td style="width: 282px; text-align:left;border-color:#000000;min-width:282px;">Involuntary termination benefits </td><td style="width: 114px; text-align:right;border-color:#000000;min-width:114px;">4.1</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">2.1</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">(0.5)</td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;">5.7</td></tr><tr style="height: 19px"><td style="width: 282px; text-align:left;border-color:#000000;min-width:282px;">Contract termination costs</td><td style="width: 114px; text-align:right;border-color:#000000;min-width:114px;">2.8</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">- </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">(1.2)</td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;">1.6</td></tr><tr style="height: 19px"><td style="width: 282px; text-align:left;border-color:#000000;min-width:282px;">Other termination costs </td><td style="width: 114px; text-align:right;border-color:#000000;min-width:114px;">- </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">2.9</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">(1.3)</td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;">1.6</td></tr><tr style="height: 19px"><td style="width: 282px; text-align:left;border-color:#000000;min-width:282px;"> </td><td style="width: 114px; text-align:right;border-color:#000000;min-width:114px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;">___________</td></tr><tr style="height: 19px"><td style="width: 282px; text-align:left;border-color:#000000;min-width:282px;"> </td><td style="width: 114px; text-align:right;border-color:#000000;min-width:114px;">6.9</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">5.0</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">(3.0)</td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;">8.9</td></tr><tr style="height: 19px"><td style="width: 282px; text-align:left;border-color:#000000;min-width:282px;"> </td><td style="width: 114px; text-align:right;border-color:#000000;min-width:114px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 117px; text-align:right;border-color:#000000;min-width:117px;">___________</td></tr></table></div>At March 31, 2010 the closing reorganization cost liability was recorded within accounts payable and accrued expenses ($4.1 million) and other non-current liabilities ($4.8 million).

</shpgf:ReorganizationItemsTextBlock>

<us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock id="ID_6485" contextRef="FROM_Jan01_2010_TO_Mar31_2010">

5. Accounts receivable, net Accounts receivable at March 31, 2010 of $620.7 million (December 31, 2009: $597.5 million), are stated net of a provision for discounts and doubtful accounts of $20.1 million (December 31, 2009: $20.8 million). Provision for discounts and doubtful accounts:<div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">2010</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">2009</td></tr><tr style="height: 17px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">$’M</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">$’M</td></tr><tr style="height: 11px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_____________</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_____________</td></tr><tr style="height: 19px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;">As at January 1,</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">20.8</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">20.2</td></tr><tr style="height: 19px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;">Provision charged to operations</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">39.5</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">32.5</td></tr><tr style="height: 19px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;">Provision utilization</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">(40.2)</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">(25.8)</td></tr><tr style="height: 11px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_____________</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_____________</td></tr><tr style="height: 19px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;">As at March 31,</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">20.1</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">26.9</td></tr><tr style="height: 11px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_____________</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_____________</td></tr></table></div>At March 31, 2010 accounts receivable included $93.2 million (December 31, 2009: $92.4 million) of receivables related to royalty income.

</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>

<us-gaap:InventoryDisclosureTextBlock id="ID_6548" contextRef="FROM_Jan01_2010_TO_Mar31_2010">

6. Inventories Inventories are stated at the lower of cost or market value and comprise:<div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td style="width: 475px; text-align:left;border-color:#000000;min-width:475px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">March 31,</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">December 31,</td></tr><tr style="height: 17px"><td style="width: 475px; text-align:left;border-color:#000000;min-width:475px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">2010</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">2009</td></tr><tr style="height: 17px"><td style="width: 475px; text-align:left;border-color:#000000;min-width:475px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">$’M</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;"> $’M</td></tr><tr style="height: 11px"><td style="width: 475px; text-align:left;border-color:#000000;min-width:475px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">____________</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">____________</td></tr><tr style="height: 19px"><td style="width: 475px; text-align:left;border-color:#000000;min-width:475px;">Finished goods</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">68.5</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">50.9</td></tr><tr style="height: 19px"><td style="width: 475px; text-align:left;border-color:#000000;min-width:475px;">Work-in-progress</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">102.9</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">102.1</td></tr><tr style="height: 19px"><td style="width: 475px; text-align:left;border-color:#000000;min-width:475px;">Raw materials</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">44.2</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">36.7</td></tr><tr style="height: 11px"><td style="width: 475px; text-align:left;border-color:#000000;min-width:475px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">____________</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">____________</td></tr><tr style="height: 19px"><td style="width: 475px; text-align:left;border-color:#000000;min-width:475px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">215.6</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">189.7</td></tr><tr style="height: 11px"><td style="width: 475px; text-align:left;border-color:#000000;min-width:475px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">____________</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">____________</td></tr></table></div>At March 31, 2010 inventories included $nil (December 31, 2009: $18.8 million) for products which have not yet received regulatory approval. Pre-approval inventories at December 31, 2009 related to VPRIV, which was granted marketing approval by the US Food and Drug Administration ("FDA") on February 26, 2010.

</us-gaap:InventoryDisclosureTextBlock>

<us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock id="ID_6489" contextRef="FROM_Jan01_2010_TO_Mar31_2010">

7. Prepaid expenses and other current assets<div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">March 31,</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">December 31,</td></tr><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">2010</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">2009</td></tr><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">$’M</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;"> $’M</td></tr><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">______________</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">____________</td></tr><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Prepaid expenses</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">42.6</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">44.9</td></tr><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Income tax receivable</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">41.1</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">- </td></tr><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Value added taxes receivable</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">21.4</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">37.3</td></tr><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Other current assets</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">25.9</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">33.0</td></tr><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">______________</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">____________</td></tr><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">131.0</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">115.2</td></tr><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">______________</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">____________</td></tr></table></div>

</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>

<us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock id="ID_6490" contextRef="FROM_Jan01_2010_TO_Mar31_2010">

8. InvestmentsOn March 12, 2009 the Company completed the disposal of its investment in Virochem Pharma Inc. ("Virochem") to Vertex in a cash and stock transaction. The disposal was part of a transaction entered into by all the shareholders of Virochem with Vertex. The carrying amount of the Company's investment in Virochem on March 12, 2009 was $14.8 million. In 2009 Shire received consideration of $19.2 million in cash and two million Vertex shares (valued at $50.8 million) from the disposal, recognizing a gain of $55.2 million in the three months to March 31, 2009. In the three months to March 31, 2010 the Company received further consideration of $2.0 million in cash and 0.2 million Vertex shares (valued at $9.1 million) which had been held in escrow until certain conditions expired in March 2010. The Company recognized an additional gain on disposal of $11.1 million in the three months to March 31, 2010. The Vertex stock received has been accounted for as an available-for-sale investment.

</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>

<us-gaap:IntangibleAssetsDisclosureTextBlock id="ID_6492" contextRef="FROM_Jan01_2010_TO_Mar31_2010">

9. Other intangible assets, net<div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td style="width: 52px; text-align:left;border-color:#000000;min-width:52px;"> </td><td style="width: 383px; text-align:left;border-color:#000000;min-width:383px;"> </td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">March 31,</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">December 31,</td></tr><tr style="height: 17px"><td style="width: 52px; text-align:left;border-color:#000000;min-width:52px;"> </td><td style="width: 383px; text-align:left;border-color:#000000;min-width:383px;"> </td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">2010</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">2009</td></tr><tr style="height: 17px"><td style="width: 52px; text-align:left;border-color:#000000;min-width:52px;"> </td><td style="width: 383px; text-align:left;border-color:#000000;min-width:383px;"> </td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">$’M</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;"> $’M</td></tr><tr style="height: 17px"><td style="width: 52px; text-align:left;border-color:#000000;min-width:52px;"> </td><td style="width: 383px; text-align:left;border-color:#000000;min-width:383px;"> </td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">________________</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">________________</td></tr><tr style="height: 17px"><td colspan="2" style="width: 435px; text-align:left;border-color:#000000;min-width:435px;">Intellectual property rights acquired</td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;"> </td></tr><tr style="height: 17px"><td style="width: 52px; text-align:left;border-color:#000000;min-width:52px;"> </td><td style="width: 383px; text-align:left;border-color:#000000;min-width:383px;">Currently marketed products</td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">2,330.1</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">2,351.6</td></tr><tr style="height: 17px"><td style="width: 52px; text-align:left;border-color:#000000;min-width:52px;"> </td><td style="width: 383px; text-align:left;border-color:#000000;min-width:383px;">IPR&D</td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">6.1</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">6.1</td></tr><tr style="height: 17px"><td colspan="2" style="width: 435px; text-align:left;border-color:#000000;min-width:435px;">Favorable manufacturing contracts</td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">8.7</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">8.7</td></tr><tr style="height: 17px"><td style="width: 52px; text-align:left;border-color:#000000;min-width:52px;"> </td><td style="width: 383px; text-align:left;border-color:#000000;min-width:383px;"> </td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">________________</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">________________</td></tr><tr style="height: 17px"><td style="width: 52px; text-align:left;border-color:#000000;min-width:52px;"> </td><td style="width: 383px; text-align:left;border-color:#000000;min-width:383px;"> </td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">2,344.9</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">2,366.4</td></tr><tr style="height: 17px"><td style="width: 52px; text-align:left;border-color:#000000;min-width:52px;"> </td><td style="width: 383px; text-align:left;border-color:#000000;min-width:383px;"> </td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;"> </td></tr><tr style="height: 17px"><td colspan="2" style="width: 435px; text-align:left;border-color:#000000;min-width:435px;">Less: Accumulated amortization</td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">(615.3)</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">(575.7)</td></tr><tr style="height: 17px"><td style="width: 52px; text-align:left;border-color:#000000;min-width:52px;"> </td><td style="width: 383px; text-align:left;border-color:#000000;min-width:383px;"> </td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">________________</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">________________</td></tr><tr style="height: 17px"><td style="width: 52px; text-align:left;border-color:#000000;min-width:52px;"> </td><td style="width: 383px; text-align:left;border-color:#000000;min-width:383px;"> </td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">1,729.6</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">1,790.7</td></tr><tr style="height: 17px"><td style="width: 52px; text-align:left;border-color:#000000;min-width:52px;"> </td><td style="width: 383px; text-align:left;border-color:#000000;min-width:383px;"> </td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">________________</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">________________</td></tr></table></div>At March 31, 2010 the net book value of intangible assets allocated to the Specialty Pharmaceuticals segment was $1,201.6 million (December 31, 2009: $1,238.0 million) and in the Human Genetics Therapies ("HGT") segment was $528.0 million (December 31, 2009: $552.7 million). The change in the net book value of other intangible assets for the three months to March 31, 2010 is shown in the table below: <div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td style="width: 573px; text-align:left;border-color:#000000;min-width:573px;"> </td><td style="width: 119px; text-align:right;border-color:#000000;min-width:119px;">Other intangible</td></tr><tr style="height: 17px"><td style="width: 573px; text-align:left;border-color:#000000;min-width:573px;"> </td><td style="width: 119px; text-align:right;border-color:#000000;min-width:119px;">assets</td></tr><tr style="height: 17px"><td style="width: 573px; text-align:left;border-color:#000000;min-width:573px;"> </td><td style="width: 119px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:119px;">$’M</td></tr><tr style="height: 11px"><td style="width: 573px; text-align:right;border-color:#000000;min-width:573px;"> </td><td style="width: 119px; text-align:left;border-color:#000000;min-width:119px;"> </td></tr><tr style="height: 17px"><td style="width: 573px; text-align:left;border-color:#000000;min-width:573px;">As at January 1, 2010</td><td style="width: 119px; text-align:right;border-color:#000000;min-width:119px;">1,790.7</td></tr><tr style="height: 17px"><td style="width: 573px; text-align:left;border-color:#000000;min-width:573px;">Acquisitions</td><td style="width: 119px; text-align:right;border-color:#000000;min-width:119px;">2.7</td></tr><tr style="height: 17px"><td style="width: 573px; text-align:left;border-color:#000000;min-width:573px;">Amortization charged </td><td style="width: 119px; text-align:right;border-color:#000000;min-width:119px;">(35.0)</td></tr><tr style="height: 17px"><td style="width: 573px; text-align:left;border-color:#000000;min-width:573px;">Foreign currency translation</td><td style="width: 119px; text-align:right;border-color:#000000;min-width:119px;">(28.8)</td></tr><tr style="height: 17px"><td style="width: 573px; text-align:right;border-color:#000000;min-width:573px;"> </td><td style="width: 119px; text-align:right;border-color:#000000;min-width:119px;">________________</td></tr><tr style="height: 17px"><td style="width: 573px; text-align:left;border-color:#000000;min-width:573px;">As at March 31, 2010</td><td style="width: 119px; text-align:right;border-color:#000000;min-width:119px;">1,729.6</td></tr><tr style="height: 17px"><td style="width: 573px; text-align:right;border-color:#000000;min-width:573px;"> </td><td style="width: 119px; text-align:right;border-color:#000000;min-width:119px;">________________</td></tr></table></div>The weighted average amortization period for acquired currently marketed products is 10 years. The Company reviews its intangible assets for impairment whenever events or circumstances suggest that they may not be recoverable. During the first quarter of 2010, as a result of continuing release liner removal specification concerns, the Company reviewed the recoverability of its DAYTRANA intangible asset, (carrying value $105 million), and based on estimates and intentions at March 31, 2010 the Company determined that its DAYTRANA intangible asset remained recoverable. However, it is reasonably possible that changes to circumstances, estimates or intentions existing at March 31, 2010 could result in impairment of the DAYTRANA intangible asset in future periods. Management estimates that the annual amortization charge in respect of intangible assets held at March 31, 2010 will be approximately $140 million for each of the five years to March 31, 2015. Estimated amortization expense can be affected by various factors including future acquisitions, disposals of product rights, regulatory approval and subsequent amortization of the acquired IPR&D projects, foreign exchange movements and the technological advancement and regulatory approval of competitor products.

</us-gaap:IntangibleAssetsDisclosureTextBlock>

<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock id="ID_6527" contextRef="FROM_Jan01_2010_TO_Mar31_2010">

10. Accounts payable and accrued expenses<div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">March 31,</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">December 31,</td></tr><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">2010</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">2009</td></tr><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">$’M</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;"> $’M</td></tr><tr style="height: 11px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">________________</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">________________</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Trade accounts payable and accrued purchases</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">149.7</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">170.6</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Accrued rebates – Medicaid</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">246.4</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">188.2</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Accrued rebates – Managed care</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">158.9</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">153.4</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Sales return reserve</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">63.9</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">62.7</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Accrued bonuses</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">30.8</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">66.8</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Accrued employee compensation and benefits payable</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">58.2</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">42.6</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Research and development accruals</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">40.3</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">53.1</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Marketing accruals</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">34.5</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">31.5</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Deferred revenue</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">34.3</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">52.2</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Other accrued expenses</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">112.2</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">108.0</td></tr><tr style="height: 11px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">________________</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">________________</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">929.2</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">929.1</td></tr><tr style="height: 11px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">________________</td><td style="width: 120px; text-align:right;border-color:#000000;min-width:120px;">________________</td></tr></table></div>

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>

<shpgf:OtherCurrentLiabilitiesDisclosureTextBlock id="ID_6499" contextRef="FROM_Jan01_2010_TO_Mar31_2010">

11. Other current liabilities<div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">March 31,</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">December 31,</td></tr><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">2010</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">2009</td></tr><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">$’M</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;"> $’M</td></tr><tr style="height: 11px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">_____________</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">_____________</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Income taxes payable</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">-</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">46.7</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Value added taxes</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">8.8</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">10.3</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Other accrued liabilities</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">27.7</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">31.0</td></tr><tr style="height: 11px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">_____________</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">_____________</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">36.5</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">88.0</td></tr><tr style="height: 11px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">_____________</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">_____________</td></tr></table></div>

</shpgf:OtherCurrentLiabilitiesDisclosureTextBlock>

<shpgf:OtherNoncurrentLiabilitiesDisclosureTextBlock id="ID_6498" contextRef="FROM_Jan01_2010_TO_Mar31_2010">

12. Other non-current liabilities<div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">March 31,</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">December 31,</td></tr><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">2010</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">2009</td></tr><tr style="height: 17px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">$’M</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;"> $’M</td></tr><tr style="height: 11px"><td style="width: 444px; text-align:right;border-color:#000000;min-width:444px;"> </td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">____________</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">____________</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Income taxes payable</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">170.0</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">170.4</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Deferred revenue</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">17.1</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">20.0</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Deferred rent</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">14.2</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">14.5</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Insurance provisions</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">20.8</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">18.3</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;">Other accrued liabilities</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">25.6</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">23.9</td></tr><tr style="height: 11px"><td style="width: 444px; text-align:right;border-color:#000000;min-width:444px;"> </td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">____________</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">____________</td></tr><tr style="height: 19px"><td style="width: 444px; text-align:left;border-color:#000000;min-width:444px;"> </td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">247.7</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">247.1</td></tr><tr style="height: 11px"><td style="width: 444px; text-align:right;border-color:#000000;min-width:444px;"> </td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">____________</td><td style="width: 121px; text-align:right;border-color:#000000;min-width:121px;">____________</td></tr></table></div>

</shpgf:OtherNoncurrentLiabilitiesDisclosureTextBlock>

<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="ID_6551" contextRef="FROM_Jan01_2010_TO_Mar31_2010">

13. Commitments and contingencies (a) Leases Future minimum lease payments under operating leases at March 31, 2010 are presented below:<div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td style="width: 527px; text-align:left;border-color:#000000;min-width:527px;"> </td><td style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"> </td><td style="width: 110px; text-align:right;border-color:#000000;min-width:110px;">Operating</td></tr><tr style="height: 17px"><td style="width: 527px; text-align:left;border-color:#000000;min-width:527px;"> </td><td style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"> </td><td style="width: 110px; text-align:right;border-color:#000000;min-width:110px;">leases</td></tr><tr style="height: 17px"><td style="width: 527px; text-align:left;border-color:#000000;min-width:527px;"> </td><td style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"> </td><td style="width: 110px; text-align:right;border-color:#000000;min-width:110px;">$’M</td></tr><tr style="height: 15px"><td style="width: 527px; text-align:left;border-color:#000000;min-width:527px;"> </td><td style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"> </td><td style="width: 110px; text-align:right;border-color:#000000;min-width:110px;">_____________</td></tr><tr style="height: 17px"><td style="width: 527px; border-color:#000000;min-width:527px;">2010</td><td style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"> </td><td style="width: 110px; text-align:right;border-color:#000000;min-width:110px;">24.0</td></tr><tr style="height: 17px"><td style="width: 527px; border-color:#000000;min-width:527px;">2011</td><td style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"> </td><td style="width: 110px; text-align:right;border-color:#000000;min-width:110px;">30.4</td></tr><tr style="height: 17px"><td style="width: 527px; border-color:#000000;min-width:527px;">2012</td><td style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"> </td><td style="width: 110px; text-align:right;border-color:#000000;min-width:110px;">18.3</td></tr><tr style="height: 17px"><td style="width: 527px; border-color:#000000;min-width:527px;">2013</td><td style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"> </td><td style="width: 110px; text-align:right;border-color:#000000;min-width:110px;">17.0</td></tr><tr style="height: 17px"><td style="width: 527px; border-color:#000000;min-width:527px;">2014</td><td style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"> </td><td style="width: 110px; text-align:right;border-color:#000000;min-width:110px;">16.9</td></tr><tr style="height: 17px"><td style="width: 527px; border-color:#000000;min-width:527px;">2015</td><td style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"> </td><td style="width: 110px; text-align:right;border-color:#000000;min-width:110px;">16.1</td></tr><tr style="height: 17px"><td style="width: 527px; text-align:left;border-color:#000000;min-width:527px;">Thereafter</td><td style="width: 75px; border-color:#000000;min-width:75px;">1</td><td style="width: 110px; text-align:right;border-color:#000000;min-width:110px;">57.6</td></tr><tr style="height: 15px"><td style="width: 527px; text-align:left;border-color:#000000;min-width:527px;"> </td><td style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"> </td><td style="width: 110px; text-align:right;border-color:#000000;min-width:110px;">_____________</td></tr><tr style="height: 19px"><td style="width: 527px; text-align:left;border-color:#000000;min-width:527px;"> </td><td style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"> </td><td style="width: 110px; text-align:right;border-color:#000000;min-width:110px;">180.3</td></tr><tr style="height: 15px"><td style="width: 527px; text-align:left;border-color:#000000;min-width:527px;"> </td><td style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"> </td><td style="width: 110px; text-align:right;border-color:#000000;min-width:110px;">_____________</td></tr></table></div>The Company leases land, facilities, motor vehicles and certain equipment under operating leases expiring through 2027. Lease and rental expense amounted to $8.6 million and $8.5 million for the three months to March 31, 2010 and 2009 respectively, which is predominately included in Selling, general and administrative expenses in the consolidated statements of income. (b) Letters of credit and guarantees At March 31, 2010 the Company had irrevocable standby letters of credit and guarantees with various banks totaling $16.0 million, providing security for the Company's performance of various obligations. These obligations are primarily in respect of the recoverability of insurance claims, lease obligations and supply commitments. The Company has restricted cash of $9.8 million, as required by these letters of credit. (c) Collaborative arrangements Details of significant collaborative arrangements are included below: In-licensing arrangements (i) Research Collaboration with Santaris Pharma A/S ("Santaris") on Locked Nucleic Acid ("LNA") Drug Platform On August 24, 2009 Shire announced that it had entered into a research collaboration with Santaris, to develop its proprietary LNA technology in a range of rare diseases. LNA technology has the benefit of shortened target validation and proof of concept, potentially increasing the speed and lowering the cost of development. As part of the joint research project Santaris will design, develop and deliver pre-clinical LNA oligonucleotides for Shire-selected orphan disease targets, and Shire will have the exclusive right to further develop and commercialize these candidate compounds on a worldwide basis.Shire has remaining obligations to pay Santaris $13.5 million subject to certain success criteria, and development and sales milestones up to a maximum of $72 million for each indication. Shire will also pay single or double digit tiered royalties on net sales of the product.Shire and Santaris have formed a joint research committee to monitor R&D activities through preclinical Lead Candidate selection at which point all development and commercialization costs will be the responsibility of Shire. (ii) JUVISTA On June 19, 2007 Shire signed an agreement with Renovo Limited ("Renovo") to develop and commercialize JUVISTA, Renovo's novel drug candidate being investigated for the reduction of scarring in connection with surgery, outside of the EU. On March 1, 2010, the license agreement was revised. In the revised license agreement, the rights to sell JUVISTA in all territories outside the USA, Mexico and Canada were returned to Renovo. Milestone and royalty obligations remain unchanged from the original agreement except that Shire will pay Renovo an additional $5 million milestone if Shire elects to commence a clinical trial following Shire's review of the clinical trial report from Renovo's first EU Phase 3 clinical trial. Shire has remaining obligations to pay Renovo $25 million on the filing of JUVISTA with the FDA; up to $150 million on FDA approval; royalties on net sales of JUVISTA; and up to $525 million on the achievement of very significant sales targets. Under the revised agreement, each party is responsible for its own development costs but future development costs can be shared by agreement. Each party has free-of-charge access to the other party's data to support regulatory filings in their respective territories. In the three months to March 31, 2010 Shire made a payment to Renovo of $3.2 million (In the three months to March 31, 2009: $nil), being the final payment under the terms of the original license agreement. Out-licensing arrangements Shire has entered into various collaborative arrangements under which the Company has out-licensed certain product or intellectual property rights for consideration such as up-front payments, development milestones, sales milestones and/or royalty payments. In certain of these arrangements Shire and the licensee are both actively involved in the development and commercialization of the licensed product and have exposure to risks and rewards dependent on its commercial success. In the three months to March 31, 2010 Shire received milestone payments totaling $nil (2009: $4.0 million). In the three months to March 31, 2010 Shire recognized milestone income of $0.7 million (2009: $1.8 million) within Other revenues and $12.8 million (2009: $5.7 million) within Product sales for shipment of product to the relevant licensee. Co-promotion agreements - VYVANSE On March 31, 2009 Shire announced a three-year co-promotion agreement with GSK for VYVANSE in the US with the aim of improving recognition and treatment of ADHD in adults. The agreement is based on profit sharing above an agreed upon baseline and these profit share payments will be included within Selling, general and administrative costs. (d) Commitments (i) Clinical testing At March 31, 2010 the Company had committed to pay approximately $145.7 million (December 31, 2009: $183.9 million) to contract vendors for administering and executing clinical trials. The Company expects to pay $80.9 million of these commitments in the remainder of 2010 (December 31, 2009: $104.1 million in 2010), however the timing of these payments is dependent upon actual services performed by the organizations as determined by patient enrollment levels and related activities. (ii) Contract manufacturing At March 31, 2010 the Company had committed to pay approximately $98.8 million (December 31, 2009: $152.3 million) in respect of contract manufacturing. The Company expects to pay all of these commitments in the remainder of 2010 (December 31, 2009: $77.3 million in 2010). (iii) Other Purchasing commitments At March 31, 2010 the Company had committed to pay approximately $59.0 million (December 31, 2009: $22.9 million) for future purchases of goods and services, predominantly relating to active pharmaceutical ingredients sourcing and IT outsourcing. The Company expects to pay $53.7 million of these commitments in the remainder of 2010 (December 31, 2009: $21.0 million in 2010). (iv) Investment commitments At March 31, 2010 the Company had outstanding commitments to subscribe for interests in companies and partnerships for amounts totaling $5.6 million (December 31, 2009: $5.4 million) which may all be payable in the remainder of 2010, depending on the timing of capital calls. (v) Capital commitments At March 31, 2010 the Company had committed to spend $16.5 million (December 31, 2009: $41.4 million) on capital projects. This includes commitments for the expansion and modification of its offices and manufacturing facilities at its HGT campus in Lexington, Massachusetts. (e) Legal and other proceedings General The Company recognizes loss contingency provisions for probable losses when management is able to reasonably estimate the loss. Where the estimated loss lies within a range and no particular amount within that range is a better estimate than any other amount, the minimum amount is recorded. In other cases management's best estimate of the loss is recorded. These estimates are developed substantially before the ultimate loss is known and the estimates are refined in each accounting period in light of additional information becoming known. In instances where the Company is unable to develop a reasonable estimate of loss, no litigation loss is recorded at that time. As information becomes known a loss provision is set up when a reasonable estimate can be made. The estimates are reviewed quarterly and are changed when expectations are revised. Any outcome upon settlement that deviates from the Company's estimate may result in an additional expense in a future accounting period. At March 31, 2010 provisions for litigation losses, insurance claims and other disputes totaled $22.4 million (December 31, 2009: $20.1 million). Specific VYVANSE On February 24, 2009 Actavis Elizabeth LLC ("Actavis") brought a lawsuit in the US District Court for the District of Columbia (the "District Court") against the FDA seeking to overturn the FDA's decision granting new chemical entity exclusivity to VYVANSE. Shire has intervened in the lawsuit. On October 23, 2009, following a period for public comment, the FDA issued a letter setting forth its analysis of the legal and regulatory issues and reaffirming its decision that VYVANSE is entitled to new chemical entity exclusivity. A hearing on cross-motions for summary judgment was held on February 17, 2010. On March 4, 2010 the District Court upheld the FDA's decision that VYVANSE is entitled to 5-year market exclusivity and confirmed that the FDA's actions complied with federal administrative law standards as a reasonable exercise of the agency's scientific expertise. Actavis has appealed the District Court's ruling to the US Court of Appeals for the DC Circuit. No hearing date has been set. FOSRENOL In February 2009 Shire was notified that three separate abbreviated new drug applications ("ANDAs") were submitted under the Hatch-Waxman Act seeking permission to market generic versions of 500mg, 750mg and 1,000mg strengths of FOSRENOL. The notices were received from Barr; Mylan, Inc., Mylan Pharmaceuticals, Inc. and Matrix Laboratories, Inc. (collectively "Mylan"); and Natco Pharma Limited ("Natco"). Within the requisite 45 day period, Shire filed lawsuits in the US District Court of the Southern District of New York against each of Barr, Mylan and Natco for infringement of certain of Shire's FOSRENOL patents. The filing of the lawsuits triggered a stay of approval of these ANDAs for up to 30 months. The lawsuits have been consolidated into a single case. A Markman hearing is scheduled to occur on June 17, 2010. No trial date has been set. INTUNIV On March 16, April 5, and April 26, 2010 Shire received Paragraph IV Notice Letters from Teva, Actavis, and Anchen Pharmaceuticals Inc. ("Anchen"), respectively, advising of the filing of ANDAs for generic versions of Shire's 1mg, 2mg, 3mg, and 4mg guanfacine hydrochloride extended release tablets, INTUNIV. INTUNIV is protected by three FDA Orange Book listed patents. The three patents expire in 2015, 2020 and 2022, respectively. Teva's Paragraph IV Notice Letter was only directed to the patents expiring in 2020 and 2022. On April 22, Shire filed a lawsuit against Teva in the US District Court for the District of Delaware for the infringement of these patents. Actavis's and Anchen's Paragraph IV Notice Letters were directed to all three Orange Book listed patents. Shire is currently reviewing the details of Actavis's and Anchen's Paragraph IV Notice Letters. CARBATROL On March 10, 2010, Shire settled the lawsuit with Nostrum Pharmaceuticals, Inc. ("Nostrum") relating to their ANDAs seeking approval to market generic versions of 100mg, 200mg and 300mg strengths of CARBATROL. No payments to Nostrum are involved in the settlement. As required by law, the Company has submitted to the US Federal Trade Commission and the US Department of Justice all of the agreements entered into as part of this settlement. REMINYL Generics UK Limited ("Generics UK") commenced an action in 2007 against the UK Medicines and Healthcare products Regulatory Agency ("MHRA") seeking judicial review of the MHRA's application of data exclusivity for REMINYL and the MHRA's corresponding refusal to grant Generics UK a marketing authorization for a generic version of REMINYL. This case was referred to the European Court of Justice ("ECJ") which decided the case in favor of the MHRA and upheld data exclusivity for REMINYL until March 2010. In separate proceedings, Generics UK commenced an action in the UK seeking a declaration to nullify the Supplementary Protection Certificate ("SPC") for EP 236684 (the patent that claims the use of galantamine for the treatment of Alzheimer's disease). This case was heard in December 2008, and the court's decision upholding the SPC (which extends the patent's term to January 2012) was handed down on May 20, 2009. Generics UK's appeal of that decision was heard on October 14, 2009 the result of which was that the case was referred to the ECJ. REPLAGAL On April 14, 2010 Mt. Sinai School of Medicine of New York University sought to initiate lawsuits in Sweden and Germany alleging that Shire's enzyme replacement therapy for Fabry disease, REPLAGAL, infringes Mt. Sinai's European Patent No. 1 942 189, granted April 14, 2010. Mt. Sinai is seeking an injunction against the use of REPLAGAL in these jurisdictions until expiration of the patent on November 30, 2013. Shire will defend its right to commercialize REPLAGAL in these countries and will vigorously oppose the validity of this patent. Subpoena related to ADDERALL XR, DAYTRANA and VYVANSE On September 23, 2009 the Company received a subpoena from the US Department of Health and Human Services Office of Inspector General in coordination with the US Attorney for the Eastern District of Pennsylvania seeking production of documents related to the sales and marketing of ADDERALL XR, DAYTRANA and VYVANSE. The Company is cooperating with this investigation.

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>

<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock id="ID_6502" contextRef="FROM_Jan01_2010_TO_Mar31_2010">

14. Derivative instruments Treasury policies and organization The Company's principal treasury operations are coordinated by its corporate treasury function. All treasury operations are conducted within a framework of policies and procedures approved annually by the Board of Directors. As a matter of policy, the Company does not undertake speculative transactions that would increase its currency or interest rate exposure. Interest rate risk The Company is exposed to interest rate risk on restricted cash, cash and cash equivalents and on foreign exchange contracts on which interest is at floating rates. This exposure is primarily to US dollar, Euro and Canadian dollar interest rates. As the Company maintains all of its investments and foreign exchange contracts on a short term basis for liquidity purposes, this risk is not actively managed. In the three months to March 31, 2010 the average interest rate received on cash and liquid investments was less than 1% per annum. The largest proportion of investments was in US dollar money market and liquidity funds. The Company incurs interest at a fixed rate of 2.75% on Shire plc's $1,100 million in principal amount convertible bonds due 2014. The building financing obligation of $46.8 million is also subject to a fixed interest rate over the lease term on the amount outstanding. No derivative instruments were entered into during the three months to March 31, 2010 to manage interest rate exposure. The Company continues to review its interest rate risk and the policies in place to manage the risk. Market risk of investments As at March 31, 2010 the Company has $109.6 million of investments comprising available-for-sale investments in publicly quoted companies ($90.9 million), equity method investments ($14.8 million) and cost method investments in private companies ($3.9 million). The investments in public quoted companies and equity method investments, for certain investment funds which contain a mixed portfolio of public and private investments, are exposed to market risk. No financial instruments or derivatives have been employed to hedge this risk. Credit risk Financial instruments that potentially expose Shire to concentrations of credit risk consist primarily of short-term cash investments, trade accounts receivable (from product sales and from third parties from which the Company receives royalties) and derivative contracts. Cash is invested in short-term money market instruments, including money market and liquidity funds and bank term deposits. The money market and liquidity funds in which Shire invests are all triple A rated by both Standard & Poor's and by Moody's credit rating agencies. The Company is exposed to the credit risk of the counterparties with which it enters into derivative contracts. The Company aims to limit this exposure through a system of internal credit limits which require counterparties to have a long term credit rating of A / A2 or better from the major rating agencies. The internal credit limits are approved by the Board of Directors and exposure against these limits is monitored by the corporate treasury function. The counterparties to the derivative contracts are major international financial institutions. The Company has entered into many agreements with third parties for the provision of services to enable it to operate its business. If the third party can no longer provide the service on the agreed basis, the Company may not be able to continue the development or commercialization of its products as planned or on a commercial basis. Additionally, it may not be able to establish or maintain good relationships with suppliers. Foreign exchange risk The Company trades in numerous countries and as a consequence has transactional and translational foreign exchange exposure. Transactional exposure arises where transactions occur in currencies different to the functional currency of the relevant subsidiary. The main trading currencies of the Company are the US dollar, the Canadian dollar, Pounds Sterling and the Euro. It is the Company's policy that these exposures are minimized to the extent practicable by denominating transactions in the subsidiary's functional currency. Where significant exposures remain, the Company uses foreign exchange contracts (being spot, forward and swap contracts) to manage the exposure in respect of balance sheet assets and liabilities that are denominated in currencies different to the functional currency of the relevant subsidiary. These assets and liabilities relate predominantly to intercompany financing and accruals for royalty receipts. The Company utilizes these derivative instruments to manage currency risk on balance sheet foreign exchange exposures but the foreign exchange contracts have not been designated as hedging instruments. Translational foreign exchange exposure arises on the translation into US dollars of the financial statements of non-US dollar functional subsidiaries. At March 31, 2010 the Company had 20 swap and forward foreign exchange contracts outstanding to manage currency risk. The swaps and forward contracts mature within 90 days. The Company did not have credit risk related contingent features or collateral linked to the derivatives. These foreign exchange contracts were classified in the consolidated balance sheet as follows:<div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td colspan="2" style="width: 490px; text-align:left;border-color:#000000;min-width:490px;"> </td><td style="width: 108px; text-align:right;border-color:#000000;min-width:108px;">Fair value</td><td style="width: 108px; text-align:right;border-color:#000000;min-width:108px;">Fair value</td></tr><tr style="height: 17px"><td style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"> </td><td style="width: 409px; text-align:left;border-color:#000000;min-width:409px;"> </td><td style="width: 108px; text-align:right;border-color:#000000;min-width:108px;">March 31,</td><td style="width: 108px; text-align:right;border-color:#000000;min-width:108px;">December 31,</td></tr><tr style="height: 17px"><td style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"> </td><td style="width: 409px; text-align:left;border-color:#000000;min-width:409px;"> </td><td style="width: 108px; text-align:right;border-color:#000000;min-width:108px;">2010</td><td style="width: 108px; text-align:right;border-color:#000000;min-width:108px;">2009</td></tr><tr style="height: 17px"><td style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"> </td><td style="width: 409px; text-align:left;border-color:#000000;min-width:409px;"> </td><td style="width: 108px; text-align:right;border-color:#000000;min-width:108px;">$’M</td><td style="width: 108px; text-align:right;border-color:#000000;min-width:108px;">$’M</td></tr><tr style="height: 14px"><td style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"> </td><td style="width: 409px; text-align:left;border-color:#000000;min-width:409px;"> </td><td style="width: 108px; text-align:right;border-color:#000000;min-width:108px;">_____________</td><td style="width: 108px; text-align:right;border-color:#000000;min-width:108px;">_____________</td></tr><tr style="height: 22px"><td style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">Assets</td><td style="width: 409px; text-align:left;border-color:#000000;min-width:409px;">Prepaid expenses and other current assets</td><td style="width: 108px; text-align:right;border-color:#000000;min-width:108px;">4.7</td><td style="width: 108px; text-align:right;border-color:#000000;min-width:108px;">5.4</td></tr><tr style="height: 22px"><td style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">Liabilities</td><td style="width: 409px; text-align:left;border-color:#000000;min-width:409px;">Other current liabilities</td><td style="width: 108px; text-align:right;border-color:#000000;min-width:108px;">1.4</td><td style="width: 108px; text-align:right;border-color:#000000;min-width:108px;">1.2</td></tr><tr style="height: 12px"><td style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"> </td><td style="width: 409px; text-align:left;border-color:#000000;min-width:409px;"> </td><td style="width: 108px; text-align:right;border-color:#000000;min-width:108px;">_____________</td><td style="width: 108px; text-align:right;border-color:#000000;min-width:108px;">_____________</td></tr></table></div>Net gains and losses (both realized and unrealized) arising on foreign exchange contracts have been classified in the consolidated statements of income as follows: <div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 75px"><td style="width: 341px; text-align:left;border-color:#000000;min-width:341px;"> </td><td style="width: 180px; text-align:left;border-color:#000000;min-width:180px;">Location of net gain recognized in income</td><td colspan="2" style="width: 198px; text-align:center;border-color:#000000;min-width:198px;">Amount of net gain recognized in income</td></tr><tr style="height: 12px"><td style="width: 341px; text-align:left;border-color:#000000;min-width:341px;"> </td><td style="width: 180px; text-align:left;border-color:#000000;min-width:180px;">__________________________________</td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">____________</td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">____________</td></tr><tr style="height: 23px"><td style="width: 341px; text-align:left;border-color:#000000;min-width:341px;">Three months to </td><td style="width: 180px; text-align:left;border-color:#000000;min-width:180px;"> </td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">March 31, </td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">March 31, </td></tr><tr style="height: 17px"><td style="width: 341px; text-align:left;border-color:#000000;min-width:341px;"> </td><td style="width: 180px; text-align:left;border-color:#000000;min-width:180px;"> </td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">2010</td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">2009</td></tr><tr style="height: 17px"><td style="width: 341px; text-align:left;border-color:#000000;min-width:341px;"> </td><td style="width: 180px; text-align:left;border-color:#000000;min-width:180px;"> </td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">$’M</td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">$’M</td></tr><tr style="height: 17px"><td style="width: 341px; text-align:left;border-color:#000000;min-width:341px;"> </td><td style="width: 180px; text-align:left;border-color:#000000;min-width:180px;"> </td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">_____________</td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">_____________</td></tr><tr style="height: 17px"><td style="width: 341px; text-align:left;border-color:#000000;min-width:341px;">Foreign exchange contracts</td><td style="width: 180px; text-align:left;border-color:#000000;min-width:180px;">Other income, net</td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">18.2</td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">30.9</td></tr><tr style="height: 11px"><td style="width: 341px; text-align:left;border-color:#000000;min-width:341px;"> </td><td style="width: 180px; text-align:left;border-color:#000000;min-width:180px;"> </td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">_____________</td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">_____________</td></tr></table></div>These net foreign exchange gains are offset within Other income, net by net foreign exchange losses arising on the balance sheet items that these contracts were put in place to manage.

</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>

<us-gaap:FairValueDisclosuresTextBlock id="ID_6505" contextRef="FROM_Jan01_2010_TO_Mar31_2010">

15. Fair value measurement Assets and liabilities that are measured at fair value on a recurring basis The following financial assets and liabilities are measured at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3).<div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td style="width: 205px; text-align:left;border-color:#000000;min-width:205px;"> </td><td style="width: 94px; text-align:right;border-color:#000000;min-width:94px;">Carrying</td><td colspan="4" style="width: 400px; text-align:center;border-color:#000000;min-width:400px;">Fair value</td></tr><tr style="height: 17px"><td style="width: 205px; text-align:left;border-color:#000000;min-width:205px;"> </td><td style="width: 94px; text-align:right;border-color:#000000;min-width:94px;">value</td><td style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"> </td><td style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"> </td><td style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"> </td><td style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"> </td></tr><tr style="height: 17px"><td style="width: 205px; text-align:left;border-color:#000000;min-width:205px;"> </td><td style="width: 94px; text-align:right;border-color:#000000;min-width:94px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">Total</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">Level 1</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">Level 2</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">Level 3</td></tr><tr style="height: 17px"><td style="width: 205px; text-align:left;border-color:#000000;min-width:205px;"> </td><td style="width: 94px; text-align:right;border-color:#000000;min-width:94px;">$'M</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">$'M</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">$'M</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">$'M</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">$'M</td></tr><tr style="height: 11px"><td style="width: 205px; text-align:right;border-color:#000000;min-width:205px;"> </td><td style="width: 94px; text-align:right;border-color:#000000;min-width:94px;">____________</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">____________</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">___________</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">___________</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">___________</td></tr><tr style="height: 17px"><td style="width: 205px; text-align:left;border-color:#000000;min-width:205px;">Financial assets:</td><td style="width: 94px; text-align:right;border-color:#000000;min-width:94px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td></tr><tr style="height: 19px"><td style="width: 205px; text-align:left;border-color:#000000;min-width:205px;">Available-for-sale securities(1)</td><td style="width: 94px; text-align:right;border-color:#000000;min-width:94px;">90.9</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">90.9</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">90.9</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">- </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">- </td></tr><tr style="height: 17px"><td style="width: 205px; text-align:left;border-color:#000000;min-width:205px;">Foreign exchange contracts</td><td style="width: 94px; text-align:right;border-color:#000000;min-width:94px;">4.7</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">4.7</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">- </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">4.7</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">- </td></tr><tr style="height: 17px"><td style="width: 205px; text-align:left;border-color:#000000;min-width:205px;"> </td><td style="width: 94px; text-align:right;border-color:#000000;min-width:94px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td></tr><tr style="height: 17px"><td style="width: 205px; text-align:left;border-color:#000000;min-width:205px;">Financial liabilities:</td><td style="width: 94px; text-align:right;border-color:#000000;min-width:94px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td></tr><tr style="height: 17px"><td style="width: 205px; text-align:left;border-color:#000000;min-width:205px;">Foreign exchange contracts</td><td style="width: 94px; text-align:right;border-color:#000000;min-width:94px;">1.4</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">1.4</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">- </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">1.4</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">- </td></tr><tr style="height: 11px"><td style="width: 205px; text-align:right;border-color:#000000;min-width:205px;"> </td><td style="width: 94px; text-align:right;border-color:#000000;min-width:94px;">____________</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">____________</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">___________</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">___________</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">___________</td></tr></table></div>(1) Available-for-sale securities are included within Investments in the consolidated balance sheet. Certain estimates and judgments were required to develop the fair value amounts. The fair value amounts shown above are not necessarily indicative of the amounts that the Company would realize upon disposition, nor do they indicate the Company's intent or ability to dispose of the financial instrument. The following methods and assumptions were used to estimate the fair value of each material class of financial instrument: <ul><li style="margin-left:36px;list-style:disc;">Available-for-sale securities – the fair values of available-for-sale securities are estimated based on quoted market prices for those investments. </li><li style="margin-left:36px;list-style:disc;">Foreign exchange contracts – the fair values of the swap and forward foreign exchange contracts have been determined using an income approach based on current market expectations about the future cash flows.</li></ul> Financial assets and liabilities that are not measured at fair value on a recurring basis The carrying amounts and estimated fair values as at March 31, 2010 and December 31, 2009 of the Company's financial assets and liabilities which are not measured at fair value on a recurring basis are as follows:<div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"> </td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td colspan="2" style="width: 199px; text-align:center;border-color:#000000;min-width:199px;">March 31, 2010</td><td colspan="2" style="width: 200px; text-align:center;border-color:#000000;min-width:200px;">December 31, 2009</td></tr><tr style="height: 17px"><td style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"> </td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">Carrying</td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">Carrying</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td></tr><tr style="height: 17px"><td style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"> </td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">amount</td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">Fair value</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">amount</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">Fair value </td></tr><tr style="height: 17px"><td style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"> </td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">$’M</td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">$’M</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">$’M</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">$’M</td></tr><tr style="height: 11px"><td style="width: 278px; text-align:right;border-color:#000000;min-width:278px;"> </td><td style="width: 19px; text-align:right;border-color:#000000;min-width:19px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">____________</td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">____________</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">____________</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">___________</td></tr><tr style="height: 17px"><td style="width: 278px; text-align:right;border-color:#000000;min-width:278px;"> </td><td style="width: 19px; text-align:right;border-color:#000000;min-width:19px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td></tr><tr style="height: 17px"><td style="width: 278px; text-align:left;border-color:#000000;min-width:278px;">Financial assets:</td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td></tr><tr style="height: 17px"><td style="width: 278px; text-align:left;border-color:#000000;min-width:278px;">Option over Avexa shares</td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">- </td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">0.1</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">- </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">0.1</td></tr><tr style="height: 17px"><td style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"> </td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td></tr><tr style="height: 17px"><td style="width: 278px; text-align:left;border-color:#000000;min-width:278px;">Financial liabilities:</td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;"> </td></tr><tr style="height: 17px"><td style="width: 278px; text-align:left;border-color:#000000;min-width:278px;">Convertible bonds</td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">1,100.0</td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">1,098.0</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">1,100.0</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">1,067.0</td></tr><tr style="height: 17px"><td style="width: 278px; text-align:left;border-color:#000000;min-width:278px;">Building financing obligation</td><td style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">46.8</td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">47.8</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">46.7</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">47.3</td></tr><tr style="height: 11px"><td style="width: 278px; text-align:right;border-color:#000000;min-width:278px;"> </td><td style="width: 19px; text-align:right;border-color:#000000;min-width:19px;"> </td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">____________</td><td style="width: 99px; text-align:right;border-color:#000000;min-width:99px;">____________</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">____________</td><td style="width: 100px; text-align:right;border-color:#000000;min-width:100px;">___________</td></tr></table></div>Certain estimates and judgments were required to develop the fair value amounts. The fair value amounts shown above are not necessarily indicative of the amounts that the Company would realize upon disposition, nor do they indicate the Company's intent or ability to dispose of the financial instrument. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate to fair value because of the short-term maturity of these amounts. The following methods and assumptions were used to estimate the fair value of each material class of financial instrument: <ul><li style="margin-left:36px;list-style:disc;">Option over Avexa shares - the fair values of the Avexa shares are based on quoted market prices for the shares.</li></ul> <ul><li style="margin-left:36px;list-style:disc;">Convertible bonds – the fair value of Shire $1,100 million 2.75% convertible bonds due 2014 is estimated by reference to the market price of the instrument as the convertible bonds are publicly traded.</li></ul> <ul><li style="margin-left:36px;list-style:disc;">Building financing obligations - the fair value of building financing obligations are estimated based on the present value of future cash flows, and an estimate of the residual value of the underlying property at the end of the lease term, associated with these obligations.</li></ul>

</us-gaap:FairValueDisclosuresTextBlock>

<us-gaap:EarningsPerShareTextBlock id="ID_6528" contextRef="FROM_Jan01_2010_TO_Mar31_2010">

16. Earnings per share The following table reconciles net income attributable to Shire plc and the weighted average ordinary shares outstanding for basic and diluted earnings per share for the periods presented:<div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;">3 months to March 31,</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;"> </td></tr><tr style="height: 17px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">2010</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">2009</td></tr><tr style="height: 17px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;">Amounts attributable to Shire plc shareholders</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">$’M</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">$’M</td></tr><tr style="height: 11px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_________________</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_________________</td></tr><tr style="height: 19px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;">Numerator for basic earnings per share</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">165.9</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">213.6</td></tr><tr style="height: 19px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;">Interest on convertible bonds, net of tax </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">8.4</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">8.4</td></tr><tr style="height: 10px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_________________</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_________________</td></tr><tr style="height: 19px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;">Numerator for diluted earnings per share</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">174.3</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">222.0</td></tr><tr style="height: 10px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_________________</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_________________</td></tr><tr style="height: 19px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;"> </td></tr><tr style="height: 10px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:left;border-color:#000000;min-width:107px;"> </td><td style="width: 107px; text-align:left;border-color:#000000;min-width:107px;"> </td></tr><tr style="height: 19px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;">Weighted average number of shares: </td><td style="width: 107px; text-align:left;border-color:#000000;min-width:107px;"> </td><td style="width: 107px; text-align:left;border-color:#000000;min-width:107px;"> </td></tr><tr style="height: 19px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">Millions</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">Millions</td></tr><tr style="height: 12px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_________________</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_________________</td></tr><tr style="height: 19px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;">Basic(1)</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">543.9</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">539.2</td></tr><tr style="height: 17px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;">Effect of dilutive shares:</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;"> </td></tr><tr style="height: 19px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;">Stock based awards to employees(2)</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">9.0</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">5.3</td></tr><tr style="height: 17px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;">Convertible bonds 2.75% due 2014(3)</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">33.2</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">32.7</td></tr><tr style="height: 14px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_________________</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_________________</td></tr><tr style="height: 17px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;">Diluted</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">586.1</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">577.2</td></tr><tr style="height: 11px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_________________</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_________________</td></tr></table></div>(1) Excludes shares purchased by the ESOT and presented by the Company as treasury stock.(2) Calculated using the treasury stock method.(3) Calculated using the "if-converted" method. The share equivalents not included in the calculation of the diluted weighted average number of shares are shown below:<div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 19px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">2010(1)</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">2009(1)</td></tr><tr style="height: 17px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;"> No. of shares</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">No. of shares</td></tr><tr style="height: 17px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">Millions</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">Millions</td></tr><tr style="height: 17px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_________________</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_________________</td></tr><tr style="height: 17px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;">Share options out of the money</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">16.1</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">16.6</td></tr><tr style="height: 17px"><td style="width: 498px; text-align:left;border-color:#000000;min-width:498px;"> </td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_________________</td><td style="width: 107px; text-align:right;border-color:#000000;min-width:107px;">_________________</td></tr></table></div>(1) In the three months to March 31, 2010 and 2009 certain stock options have been excluded from the calculation of diluted Earnings per share because their exercise prices exceeded Shire plc's average share price during the calculation period.

</us-gaap:EarningsPerShareTextBlock>

<us-gaap:SegmentReportingDisclosureTextBlock id="ID_6553" contextRef="FROM_Jan01_2010_TO_Mar31_2010">

17. Segmental reporting Shire's internal financial reporting is in line with its business unit and management reporting structure and includes two segments: Specialty Pharmaceuticals and HGT. The Specialty Pharmaceuticals and HGT reportable segments represent the Company's revenues and costs for currently promoted and sold products, together with the costs of developing projects for future commercialization. 'All Other' has been included in the table below in order to reconcile the two operating segments to the total consolidated figures. The Company evaluates performance based on revenue and operating income. The Company does not have inter-segment transactions. Assets that are directly attributable or allocable to the segments have been separately disclosed. <div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 36px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">Specialty Pharmaceuticals</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">HGT</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">All Other</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">Total</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">3 months to March 31, 2010</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">$’M</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">$’M</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">$’M</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">$’M</td></tr><tr style="height: 11px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Product sales</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">541.4</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">176.8</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">- </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">718.2</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Royalties</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">58.6</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">- </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> 36.7</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">95.3</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Other revenues</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">0.7</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">0.7</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> 1.3</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">2.7</td></tr><tr style="height: 11px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Total revenues</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">600.7</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">177.5</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">38.0</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">816.2</td></tr><tr style="height: 11px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td></tr><tr style="height: 17px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;"> </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Cost of product sales(1)</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">80.4</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">21.5</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">-</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">101.9</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Research and development(1)</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">73.9</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">57.1</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">-</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">131.0</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Selling, general and administrative(1)</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">249.5</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">62.7</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">47.7</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">359.9</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Reorganization costs</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">3.4</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">- </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">1.6</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">5.0</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Integration and acquisition costs</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">0.6</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">- </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">- </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">0.6</td></tr><tr style="height: 11px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">_____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Total operating expenses</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">407.8</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">141.3</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">49.3</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">598.4</td></tr><tr style="height: 11px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">_____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Operating income/(loss)</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">192.9</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">36.2</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">(11.3)</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">217.8</td></tr><tr style="height: 11px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">_____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td></tr><tr style="height: 19px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;"> </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Total assets</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">1,997.6</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">1,613.1</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">1,128.0</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">4,738.7</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Long-lived assets(2)</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">184.6</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">436.2</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">53.7</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">674.5</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Capital expenditure on long-lived assets(2)</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">2.3</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">25.5</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">1.9</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">29.7</td></tr><tr style="height: 11px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">_____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td></tr></table></div>(1) Depreciation from manufacturing plants ($8.6 million) and amortization of favorable manufacturing contracts ($0.4 million) is included in Cost of product sales; depreciation of research and development assets ($3.7 million) is included in Research and development; and all other depreciation and amortization ($51.6 million) is included in Selling, general and administrative.(2) Long-lived assets comprise all non-current assets, excluding goodwill and other intangible assets, deferred tax assets, investments, income tax receivable and financial instruments. <div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 36px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">Specialty Pharmaceuticals</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">HGT</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">All Other</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">Total</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">3 months to March 31, 2009</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">$’M</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">$’M</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">$’M</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">$’M</td></tr><tr style="height: 11px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Product sales</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">632.5</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">123.5</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">- </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">756.0</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Royalties</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">0.9</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">- </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> 49.7</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">50.6</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Other revenues</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">7.0</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">1.4</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> 2.8</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">11.2</td></tr><tr style="height: 11px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Total revenues</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">640.4</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">124.9</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> 52.5</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">817.8</td></tr><tr style="height: 11px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td></tr><tr style="height: 17px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;"> </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Cost of product sales(1)</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">61.2</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">19.9</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">2.5</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">83.6</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Research and development(1)</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">126.6</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">56.8</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">2.5</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">185.9</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Selling, general and administrative(1)</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">229.8</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">46.0</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">43.1</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">318.9</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Reorganization costs</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">2.2</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">- </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">- </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">2.2</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Integration and acquisition costs</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">0.7</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">0.7</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">- </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">1.4</td></tr><tr style="height: 11px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">_____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Total operating expenses</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">420.5</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">123.4</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">48.1</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">592.0</td></tr><tr style="height: 11px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">_____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Operating income</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">219.9</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">1.5</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">4.4</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">225.8</td></tr><tr style="height: 11px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">_____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td></tr><tr style="height: 19px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;"> </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;"> </td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Total assets</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">2,302.6</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">1,194.0</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">791.0</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">4,287.6</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Long-lived assets(2)</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">203.8</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">296.2</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">63.3</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">563.3</td></tr><tr style="height: 20px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;">Capital expenditure on long-lived assets(2)</td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">7.0</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">39.5</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">4.0</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">50.5</td></tr><tr style="height: 11px"><td style="width: 276px; text-align:left;border-color:#000000;min-width:276px;"> </td><td style="width: 122px; text-align:right;border-color:#000000;min-width:122px;">_____________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td><td style="width: 103px; text-align:right;border-color:#000000;min-width:103px;">___________</td></tr></table></div>(1) Depreciation from manufacturing plants ($3.6 million) and amortization of favorable manufacturing contracts ($0.4 million) is included in Cost of product sales; depreciation of research and development assets ($4.0 million) is included in Research and development; and all other depreciation and amortization ($47.3 million) is included in Selling, general and administrative.(2) Long-lived assets comprise all non-current assets, (excluding goodwill and other intangible assets, deferred tax assets, investments, income tax receivable and financial instruments).

</us-gaap:SegmentReportingDisclosureTextBlock>

<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">

<link:loc xlink:type="locator" xlink:href="#ID_5884" xlink:label="ID_5884"/>

<link:footnote xlink:type="resource" xlink:label="footnote_26" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"> Cost of product sales includes amortization of intangible assets relating to favorable manufacturing contracts of $0.4 million for three months to March 31, 2010 (2009: $0.4 million). Selling, general and administrative costs includes amortization of intangible assets relating to intellectual property rights acquired of $34.6 million for the three months to March 31, 2010 (2009: $32.5 million). </link:footnote>

<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="ID_5884" xlink:to="footnote_26" order="1.0"/>

<link:loc xlink:type="locator" xlink:href="#ID_5890" xlink:label="ID_5890"/>

<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="ID_5890" xlink:to="footnote_26" order="1.0"/>

<link:loc xlink:type="locator" xlink:href="#ID_5885" xlink:label="ID_5885"/>

<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="ID_5885" xlink:to="footnote_26" order="1.0"/>

<link:loc xlink:type="locator" xlink:href="#ID_5891" xlink:label="ID_5891"/>

<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="ID_5891" xlink:to="footnote_26" order="1.0"/>

</link:footnoteLink>

</xbrli:xbrl>

↑Top

Filing Submission 0000950103-10-001332 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Shire plc – ‘10-Q’ for 3/31/10 – ‘EX-101.INS’

On: Thursday, 5/6/10, at 12:51pm ET · For: 3/31/10 · Accession #: 950103-10-1332 · File #: 0-29630

Previous ‘10-Q’: ‘10-Q’ on 11/6/09 for 9/30/09 · Next: ‘10-Q’ on 8/9/10 for 6/30/10 · Latest: ‘10-Q’ on 11/1/18 for 9/30/18

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34Filing Table of Contents

‘EX-101.INS’ — XBRL Instance — shpgf-20100331

This Exhibit is an XBRL XML File.

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents